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ABSTRACT 
Role of Ataxia-Telangiectasia Mutated Kinase in Cardiac Autophagy and Glucose Metabolism 
Under Ischemic Conditions  
by 
Patsy R. Thrasher 
Ataxia-telangiectasia mutated kinase (ATM), a serine/threonine kinase primarily located in the 
nucleus, is typically activated in response to DNA damage. Individuals with mutations in ATM 
gene develop a disease called Ataxia telangiectasia (AT). These individuals are more susceptible 
to ischemic heart disease and metabolic disorder. Our lab has previously shown that ATM plays 
a critical role in β-adrenergic receptor (β-AR) - and myocardial infarction (MI)-stimulated 
myocyte apoptosis and cardiac remodeling. This study tested the hypothesis that ATM plays a 
critical role in cardiac autophagy and glucose metabolism following MI and ischemia, 
respectively. Early during MI (4 hours after its onset) and 4 hours post-treatment with ATM 
inhibitor KU-55933, ATM deficiency resulted in autophagic impairment in the heart and in 
cardiac fibroblasts, respectively. Such autophagic changes in the heart and in cardiac fibroblasts 
associated with the activation of GSK-3β and mTOR, and inactivation of Akt and AMPK. ATM 
deficiency also augmented autophagy in the infarct region of the heart 28 days post-MI as well as 
in cardiac fibroblasts treated with ATM inhibitor KU-55933 for 24 hours. Autophagic changes in 
the infarct region during ATM deficiency associated with enhanced Akt, Erk1/2, and mTOR 
activation. Additionally, the lack of ATM accelerated glycolysis and gluconeogenesis and 
augmented TCA cycle metabolism under non-ischemic conditions. Following a 20 minute global 
ischemic period, the glycolytic pathway, not the gluconeogenic pathway, was down-regulated 
during ATM deficiency which was found to be associated with alterations in TCA cycle 
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metabolism. Such metabolic rearrangements associated with changes in the phosphorylation of 
Akt, GSK-3β, and AMPK alongside alterations in Glut4 protein expression. Thus, ATM 
deficiency impairs autophagy early after the onset of MI and in cardiac fibroblasts treated with 
ATM inhibitor KU-55933 for 4 hours. In contrast, ATM deficiency appears to augment 
autophagy late post-MI in the infarct region of the heart and in cardiac fibroblasts treated with 
ATM inhibitor KU-55933 for 24 hours. Lack of ATM alters glucose and TCA cycle metabolism 
with and without ischemia. Such findings implicate ATM as a key player in autophagic changes 
in the heart in response to MI as well as in glucose metabolism under non-ischemic and ischemic 
conditions.   
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CHAPTER 1 
INTRODUCTION 
Myocardial Infarction and Heart Failure 
Heart failure is the leading cause of death worldwide; in fact, 17.3 million of the 54 
million total deaths in the world in 2013 were due to cardiovascular disease. Roughly 92.1 
million adults in the United States have at least one type of cardiovascular disease and those 
numbers are expected to increase (Go et al. 2017). Heart disease can occur in response to many 
conditions like coronary artery disease, chronic hypertension, atherosclerosis, and myocardial 
infarction (MI) (Frangogiannis 2008). MI ultimately leads to heart failure by initiating a cascade 
of events collectively known as left ventricular remodeling (LV remodeling/cardiac remodeling), 
a process characterized by changes in ventricular function, shape, and size (Sutton and Sharpe 
2000). LV remodeling is divided into an early phase (within 72 hours post infarction) and a late 
phase (beyond 72 hours post infarction) (Sutton and Sharpe 2000). Within hours of MI, cardiac 
myocytes (the fundamental contractile cell of the myocardium) begin to undergo apoptosis 
(Sutton and Sharpe 2000; Shih et al. 2010). Cardiac myocyte apoptosis triggers expansion of the 
infarcted area (early phase cardiac remodeling) that is subsequently followed by myocardial 
hypertrophy, cardiac fibrosis, and a deterioration of contractile function (late phase cardiac 
remodeling) (Sutton and Sharpe 2000; Shih et al. 2010). Collectively, this process results in a 
poorly functioning left ventricle that progresses to heart failure (Sutton and Sharpe 2000; Shih et 
al. 2010).  
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Autophagy and Heart Failure 
Autophagy is a conserved physiological process in the body that ultimately results in the 
packaging of damaged cytoplasmic components into autophagosomes that fuse to lysosomes for 
degradation (Klionsky et al. 2007; Meijer and Codogno 2009; Jimenez et al. 2014; Bravo-San 
Pedro et al. 2017). Autophagy consist of three main phases: 1) induction and phagophore 
formation, 2) phagophore elongation and autophagosome formation, and 3) lysosomal fusion, 
degradation, and recycling (Mizushima 2007). Autophagy is critical to cellular homeostasis both 
under normal and stressful conditions. Despite its beneficial role, insufficient or excessive 
autophagic activity can result in the development of diseases such as cancer and heart failure 
(Meijer and Codogno 2009; Jimenez et al. 2014; Bravo-San Pedro et al. 2017). In fact, 
autophagic vesicles are present in the heart tissue of patients with idiopathic dilated 
cardiomyopathy (Kostin et al. 2003) and defects in the autophagy-lysosomal pathway is a 
characteristic of Danon disease (Gustafsson and Gottlieb 2009). While autophagy can serve as an 
alternate pro-survival pathway to apoptosis, excessive autophagic flux can lead to apoptosis. 
Because of the complex nature of the process, it is not always clear whether autophagy is 
detrimental or beneficial in different situations, especially in stressful situations. However, 
autophagy is suggested to play a significant role in cardiac remodeling, particularly following 
MI. Studies have shown that autophagy promotes the survival of cardiac myocytes during 
myocardial ischemia and even reduces infarct size and attenuates adverse cardiac remodeling 
post-MI (Kanamori, Takemura, Goto, Maruyama, Ono, et al. 2011; Wu et al. 2014). Moreover, 
defects in autophagy have been linked to cardiac dysfunction and heart failure (Ilkun and 
Boudina 2013). Thus, autophagy is considered cardioprotective and a potential therapeutic target 
for the treatment of heart disease.    
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Metabolism and Heart Failure 
The heart is the most ATP-consuming organ in the body, utilizing 6 kg of ATP to pump 
10 tons of blood daily (Wang et al. 2014; Lopaschuk 2016). Due to the low cardiac ATP reserve, 
the heart requires constant ATP synthesis to maintain contraction and relaxation (Wang et al. 
2014). To achieve constant ATP synthesis, the heart utilizes a wide array of metabolic substrates 
like free fatty acids (FFAs), glucose, lactate, and even ketones (Nagoshi et al. 2011; Doenst et al. 
2013; Wang et al. 2014; Lopaschuk 2016). Under normal physiological conditions, both fatty 
acids and carbohydrates like glucose serve as the main fuels to sustain cardiac function (Nagoshi 
et al. 2011; Lopaschuk 2016). However, under stressful conditions like ischemia, there is a shift 
in metabolic substrate utilization from FFA oxidation to carbohydrate oxidation, an effort that is 
thought to preserve the mechanical function and efficiency of the heart and enhance the recovery 
of post-ischemic function (Lopaschuk 2016). Interestingly this shift from FFA oxidation to 
carbohydrate oxidation, particularly glucose oxidation, is the normal adaptive response of the 
failing heart (Nagoshi et al. 2011; Doenst et al. 2013; Wang et al. 2014). However, studies have 
shown that there are no major metabolic substrate alterations in early-stage heart failure (Recchia 
et al. 1998; Funada et al. 2009; Wang et al. 2014). In fact, there are normal rates of FFA and 
glucose metabolism during the early stages of pacing-induced heart failure in dogs (Recchia et 
al. 1998). Furthermore, a study assessing metabolic substrate utilization by the failing human 
heart using arterio-venous blood sampling demonstrated that FFA uptake was similar in patients 
with early-stage heart failure compared to controls, a phenomenon that has mostly been 
attributed to the wide range of compensatory processes that occur during the early stages of heart 
failure (Funada et al. 2009). However, during end-stage or advanced decompensated heart failure 
FFA uptake is significantly reduced while glucose metabolism is increased (Wang et al. 2014), a 
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phenomenon that may be attributed to the fact that glucose metabolism is more oxygen efficient 
than FFA metabolism (Doenst et al. 2013). In fact, an evaluation of myocardial FFA and glucose 
uptake in patients with congestive heart failure revealed that FFA uptake decreased while 
glucose uptake increased in those heart (Taylor et al. 2001) and glucose metabolism is increased 
in cardiac hypertrophy (Kolwicz and Tian 2011). Thus, metabolic therapy has been proposed as a 
novel means of enhancing cardiac energetics and function in the failing heart (Nagoshi et al. 
2011; Doenst et al. 2013; Wang et al. 2014). Because glucose uptake is increased during end-
stage heart failure, therapies that promote glucose utilization while suppressing FFA metabolism 
have gained considerable attention (Nagoshi et al. 2011; Doenst et al. 2013; Wang et al. 2014). 
 
Ataxia-Telangiectasia Mutated Kinase and Ataxia Telangiectasia Disorder 
Ataxia Telangiectasia Mutated Kinase (ATM) is a 370 kDa serine/threonine kinase 
located primarily in the nucleus where its primary function is to control cell cycle progression 
following double-stranded DNA breaks (Matsuoka et al. 1998; Rotman and Shiloh 1998; Yang 
and Kastan 2000; Abraham 2001; Peretz et al. 2001; Guinea Viniegra et al. 2005; Schneider et 
al. 2006; Halaby et al. 2008). Following DNA damage, ATM is activated via the 
autophosphorylation of several phosphorylation sites such as S2996, S367, S1893, and S1981 
(Bakkenist and Kastan 2003; Kozlov et al. 2006). Active ATM then phosphorylates a plethora of 
downstream targets that are involved in cell cycle arrest (Banin et al. 1998; Matsuoka et al. 
1998). For example, ATM activates p53 and Chk2, proteins critical in checkpoint-mediated cell 
cycle arrest (Banin et al. 1998; Matsuoka et al. 1998). Although the most widely known function 
of ATM is DNA damage repair, ATM also resides in the cytoplasm where it plays a critical role 
in regulating responses to many genotoxic stresses (Watters et al. 1999; Yang and Kastan 2000). 
15 
 
For instance, oxidative stress activates ATM (Guo et al. 2010). In fact, reactive oxygen species 
(ROS) can activate ATM directly (Guo et al. 2010). ROS levels are high in the cerebella of 
ATM-deficient mouse brains and there are abnormalities in antioxidant systems in ATM-
deficient cells and tissues (Barzilai et al. 2002). Additionally, ATM-deficient mice exhibit 
alterations in levels of several compounds involved in oxidative stress (Barzilai et al. 2002). 
ATM-deficient mice experienced increased activity of thioredoxin coupled with a significant 
decrease in catalase activity and a significant increase in MnSOD (SOD2) in the cerebella 
(Barzilai et al. 2002). Such alterations indicate the progressive deterioration of the redox balance 
in ATM-deficient mice (Barzilai et al. 2002). ATM-deficient cells also exhibit mitochondrial 
dysfunction as they experience an increase in mitochondrial numbers, a phenomenon that has 
been attributed to impaired mitophagy (Valentin-vega et al. 2012).  
Ataxia Telangiectasia (AT) is a rare multisystemic disease resulting from mutations in the 
ATM gene (Yang and Kastan 2000; Peretz et al. 2001; Halaby et al. 2008). Mutations in the ATM 
gene can result in either protein instability and complete functional loss or it can cause a decrease 
in the amount of functional protein or a decrease in kinase activity (Stewart et al. 2001; 
McKinnon 2004). The latter does not typically result in a severe phenotype as such mutations do 
not result in the complete absence of a functional ATM protein (Stewart et al. 2001; McKinnon 
2004). Individuals with a mutation in one allele, ATM heterozygotes, make up roughly 1.4-2% 
of the population (Lavin et al. 1995; Khanna et al. 2001). Patients with AT can experience 
growth retardation, immunodeficiency, cancer susceptibility, cerebellar ataxia, insulin resistance, 
γ-radiation hypersensitivity, etc (Yang and Kastan 2000; Peretz et al. 2001; Guinea Viniegra et 
al. 2005; Schneider et al. 2006; Halaby et al. 2008). These individuals are also more susceptible 
to ischemic heart disease (Lavin et al. 1995; Khanna et al. 2001) and carriers of a mutated allele 
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are at a higher risk of death between ages 20 and 79 compared to non-carriers (Su and Swift 
2000). On average, carriers of a mutates allele die 7 to 8 years younger than non-carriers with 
ischemic heart disease being the second cause of death in these individuals next to cancer (Su 
and Swift 2000).   
 
ATM and the Heart 
ATM expression in the heart 
Catecholamines, such a norepinephrine, are released during myocardial ischemia and, 
when accumulated, may contribute to ischemic heart disease and heart failure (Foster, Singh, et 
al. 2012). Norepinephrine, acting via β-adrenergic receptor (β-AR) stimulation, induces cardiac 
myocyte apoptosis and myocardial remodeling (Singh et al. 2000; Krishnamurthy et al. 2007). In 
an effort to uncover the effect of β-AR stimulation on the expression of apoptosis-related genes, 
our laboratory used gene array technique to examine the expression of 96 apoptosis-related genes 
in sham and isoproterenol-infused hearts (isoproterenol is a synthetic catecholamine) (Foster, 
Singh, et al. 2012). It was found that β-AR stimulation decreased Bcl-2 expression but increased 
BNIP-3 expression in the heart (Foster, Singh, et al. 2012). However, involvement of BNIP-3 
and Bcl-2 in cardiac myocyte apoptosis and myocardial remodeling had previously been 
examined (Gálvez et al. 2006; Diwan et al. 2007; Hamacher-Brady et al. 2007). What was 
interesting  to observe was that ATM expression increased in hearts following β-AR stimulation 
with isoproterenol (Foster, Singh, et al. 2012). Furthermore, it was observed that ATM mRNA 
increased ~2.5 fold following β-AR stimulation with isoproterenol in cardiac myocytes (Foster, 
Singh, et al. 2012). Thus, our laboratory was the first lab to show that cardiac myocytes express 
ATM at basal levels and that β-AR stimulation increases ATM expression in vivo and in vitro 
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(Foster, Singh, et al. 2012). These data were further confirmed by increased expression of ATM 
in the heart following injuries, providing evidence that ATM protein levels increase in both the 
non-infarct and infarct regions of wild-type (WT) and ATM heterozygous knockout (hKO) 
hearts 1 and 3 days post-MI (Daniel et al. 2014).  
ATM and heart function 
Using ATM knockout (KO) mice to investigate the connection between the lack of ATM 
and basal cardiac structure and function, our laboratory previously provided evidence that ATM 
KO mice had lower left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic 
diameter (LVESD), left ventricular end-systolic volume (LVESV), systolic and diastolic septal 
wall thicknesses, and LV mass (Foster, Zha, et al. 2012). However, there were no significant 
changes in fractional shortening (%FS) and ejection fraction (%EF) (Foster, Zha, et al. 2012). 
Interestingly, myocardial fibrosis and myocyte cross-sectional area or hypertrophy, both key 
components in regulating heart function, were higher in KO hearts compared to WT hearts 
(Foster, Zha, et al. 2012). Since myocyte hypertrophy serves as a compensatory mechanism that 
improves heart function following hemodynamic overload (St et al. 2000), it is possible that %FS 
and EF are sustained in KO hearts by myocyte hypertrophy even though myocardial fibrosis is 
increased. These results also pointed in the direction of diastolic impairment in the absence of 
ATM under basal conditions.     
Although the lack of ATM did not result in decreased in %FS and EF in the heart under 
basal conditions, studies investigating the role of ATM deficiency in cardiac function post-MI 
revealed that ATM deficiency does not have the same effect on cardiac remodeling early post-MI 
as it does late post-MI. In studies investigating the structure and function of the heart 1, 3, and 7 
days post-MI in ATM hKO mice, m-mode echocardiography revealed that ATM hKO mice have 
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lower left ventricular (LV) diameters and volumes as well as increased %FS and EF 1, 3, and 7 
days post-MI (Foster et al. 2013; Daniel et al. 2014). Additionally, ATM deficient mice 
experienced increased myocardial fibrosis and alpha-smooth muscle actin expression 3 and 7 
days post-MI (Foster et al. 2013; Daniel et al. 2014). Alpha-smooth muscle action (α-SMA) is a 
marker of myofibroblast differentiation and serves as a key indicator of myocardial fibrosis as 
myofibroblasts are the primary source of fibrosis deposition post-MI (Foster et al. 2013; Daniel 
et al. 2014). Furthermore, ATM deficient hearts had increased infarct thickness 7 days post-MI 
(Foster et al. 2013), a phenomenon that may serve as a by-product of increased myofibroblast 
differentiation in ATM deficient hearts and aid in mitigating LV dysfunction early post-MI.   
On the contrary, chronic MI resulted in LV dysfunction during ATM deficiency (Daniel 
et al. 2016). A study exploring cardiac function and remodeling in ATM hKO mice 14 and 28 
days post-MI showed that ATM deficiency results in decreased %FS and EF as well as increased 
LVESV (Daniel et al. 2016). ATM deficient mice also had increased myocyte apoptosis, fibrosis, 
and myocyte hypertrophy (Daniel et al. 2016), all typical characteristics of heart failure during 
the later stages of MI. Interestingly, a similar phenomenon occurred in ATM deficient hearts 28 
days following β-AR stimulation as evidenced by a decrease in %FS and EF together with 
increase in myocyte apoptosis and fibrosis (Foster, Singh, et al. 2012). Together, these results 
provide evidence that ATM is versatile, playing a protective role in the heart early after injury, 
but playing a detrimental role late after injury.  
ATM and myocyte apoptosis and cardiac fibrosis  
As the primary contractile cell in the heart, myocytes play a significant role in cardiac 
remodeling, putting myocyte apoptosis at the center of structural and functional changes in the 
heart during cardiac remodeling (Walker and Spinale 1999; Haunstetter and Izumo 2000; Nadal-
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Ginard et al. 2003). p53 is a downstream target of ATM and activation of p53 prompts the 
expression of pro-apoptotic genes like Bax (Toshiyuki and Reed 1995). Investigation of the role 
of ATM deficiency in myocyte apoptosis 28 days post β-AR stimulation, ATM heterozygosity 
resulted in an increase in myocyte apoptosis (Foster, Singh, et al. 2012). However, the 
expression and phosphorylation of p53 and expression of Bax increased to a similar extent in 
WT and hKO hearts following β-AR stimulation (Foster, Singh, et al. 2012). Conversely, 
myocyte apoptosis increased roughly 0.4 fold in both WT and KO hearts 24 hours following β-
AR stimulation (Foster, Zha, et al. 2012). In WT hearts only, β-AR stimulation resulted in the 
expression and phosphorylation of p53 and phosphorylation of JNK (Foster, Zha, et al. 2012). 
On the other hand, β-AR stimulation resulted in a decrease in Akt phosphorylation in KO hearts 
compared to WT hearts (Foster, Zha, et al. 2012). Together, these studies suggest that p53 and 
JNK pathways may be involved in β-AR-stimulated myocyte apoptosis in WT hearts, while Akt-
dependent pathways may play a role in regulating apoptosis in KO hearts. Interestingly, Akt 
phosphorylation was lower in the infarct region of ATM deficient hearts 1 day post-MI 
compared to hKO-sham and WT-MI hearts (Daniel et al. 2014). This phenomenon further 
implicates Akt-dependent pathways in myocyte apoptosis during ATM deficiency, particularly 
post injury.   
Myocardial fibrosis is characterized by an accumulation of extracellular matrix (ECM) 
proteins in the interstitium and plays an important role in the development of heart failure by 
acting on systolic and diastolic dysfunction (Kong et al. 2014). Fibroblasts produce enzymes 
such as matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) 
that influence ECM homeostasis and are key in the deposition of fibrosis in the myocardium 
(Fan et al. 2012). Myocardial fibrosis and MMP-2 protein levels significantly increased in ATM 
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deficient hearts under basal conditions and 28 days post-β-AR stimulation (Foster, Zha, et al. 
2012; Foster, Singh, et al. 2012). However, TIMP-2, an MMP-2 inhibitor, decreased in ATM 
deficient hearts 28 days post-β-AR stimulation (Foster, Singh, et al. 2012). These results 
implicate MMP-2 in myocardial fibrosis at basal levels and following β-AR stimulation during 
ATM deficiency. Contrarily, ATM deficiency resulted in an increase in MMP-9 protein 
expression in the infarct region of the heart 7 days following MI (Foster et al. 2013). However, 
28 days post-MI ATM deficiency resulted in an increase in fibrosis and a decrease in MMP-9 
protein expression in the non-infarct region of the heart (Daniel et al. 2016). These results 
provide evidence that, unlike in the case of β-AR stimulation, MMP-9 plays a role in fibrosis 
post-MI.     
ATM and cardiac inflammation  
 An inflammatory response is vital to cardiac remodeling and repair in response to insults 
such as MI (Frangogiannis 2008). Following MI, neutrophils infiltrate the infarcted area of the 
heart to remove dead cells (Frangogiannis 2008). Subsequently, macrophages engulf apoptotic 
neutrophils that lead to the production of anti-inflammatory cytokines (Frangogiannis 2008). One 
of the major anti-inflammatory cytokines produced is transforming growth factor β (TGF-β), 
which plays a role in myofibroblast differentiation and cardiac remodeling (Frangogiannis 2012).  
 Investigation of the role of ATM deficiency in the inflammatory response post-MI 
revealed that the number of neutrophils and macrophages dramatically increased in the infarct 
region of WT and hKO hearts 1 and 3 days post-MI compared to their respective shams (Daniel 
et al. 2014). Although there was no difference in the number of neutrophils and macrophages in 
the infarct region of hKO hearts 3 days post-MI, there was a significant decrease in the number 
of neutrophils and macrophages in the infarct region of hKO hearts 1 day post-MI (Daniel et al. 
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2014). Additionally, TGF-β protein expression was lower in the infarct region of hKO hearts 3 
days post-MI (Daniel et al. 2014). Collectively, these studies provide evidence that deficiency of 
ATM delays the inflammatory response in the heart early following MI, which may help explain 
improved LV function early post-MI during ATM deficiency.  
 
ATM and Autophagy 
As mentioned prior, autophagy is a catabolic process that functions to remove selected 
cytoplasmic components to maintain cellular homeostasis (Stagni et al. 2018). Autophagy is 
triggered by several phenomena, including nutrient starvation, mitochondrial dysfunction, 
hypoxia, etc (Stagni et al. 2018). Interestingly, cytoplasmic ATM is also activated in response to 
the same stressors (Stagni et al. 2018). In fact, ATM is shown to play a role in autophagy 
induction especially in cancer models (Farooqi et al. 2014; Stagni et al. 2018). Autophagy was 
induced in colorectal cancer cells treated with a low dose of camptothecin; furthermore, 
autophagy inhibitors enhanced apoptosis in these cell (Farooqi et al. 2014). Head and neck 
cancer cells treated with KU-55933, a specific ATM inhibitor, demonstrated increased 
autophagy and treating those cells with autophagy inducers increased KU-55933- induced 
apoptosis (Farooqi et al. 2014). Additionally, there is evidence that ATM activates the AMPK-
ULK1 pathway, a pathway that is known to induce autophagy, in U87MG and U251 glioma cell 
lines (Farooqi et al. 2014). There is recent evidence suggesting that ATM mediates its effects on 
autophagy via mTOR regulation (Farooqi et al. 2014; Stagni et al. 2018). It has been 
demonstrated that ATM activates the TSC2 tumor suppressor via the LKB1/AMPK pathway in 
the breast cancer cell line MCF-7 to repress mTORC1 and induce autophagy in response to 
elevated ROS (Alexander et al. 2010). ATM is also shown to regulate autophagy by sustaining 
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levels and activity of ATG4C protease in cancer cells grown as mammospheres (Antonelli et al. 
2017).  
ATM and Metabolism 
AT patients have an increased risk of developing metabolic diseases such as 
hypertension, insulin resistance, impaired glucose metabolism, and diabetes (Stracker et al. 2013; 
Takagi et al. 2015; Dahl and Aird 2017). In fact, it has been shown that 17% of AT patients 
develop type 2 diabetes mellitus and ATM-/-, ATM+/- /ApoE-/-, and ATM-/- /ApoE-/- mice suffer 
from glucose intolerance (Takagi et al. 2015). In addition to showing that ATM-/- mice were 
glucose intolerant with a condition that mimicked type 2 diabetes mellitus, Takagi et al. also 
showed that ATM+/- male mice fed a high-fat diet had abnormal adipose distribution (Takagi et 
al. 2015). Analysis of brain glucose metabolism in humans with AT and their asymptomatic 
relatives revealed fluctuations in glucose metabolism in AT patients compared to their 
asymptomatic relatives and unrelated controls (Volkow et al. 2014). AT patients had lower 
metabolism in the fusiform gyrus, cerebellar hemispheres, hippocampus, and anterior vermis 
compared to siblings or controls (Volkow et al. 2014). AT patients had higher metabolism in the 
globus pallidus that associated with negative motor performance compared to controls or siblings 
(Volkow et al. 2014).  
ATM signaling has been linked to inulin signaling and subsequent metabolic regulation 
(Bar et al. 1978; Dahl and Aird 2017). Bar et al. showed that monocytes of AT patients have a 
decreased binding affinity for insulin when compared to their unaffected counterparts (Bar et al. 
1978). It has been proposed that ATM signaling through p53 plays a critical role in both insulin 
resistance and glucose homeostasis (Dahl and Aird 2017). Once activated, ATM phosphorylates 
and activates p53 which in turn can suppress glycolysis via a plethora of pathways (Dahl and 
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Aird 2017). p53 can regulate the SLC2A and SLC2A4 genes that encode for the glucose 
transporters GLUT1 and GLUT4 (Dahl and Aird 2017). p53 can also inhibit IKK and activate 
TIGAR to regulate glycolysis (Dahl and Aird 2017). Additionally, KU-55933, a specific ATM 
inhibitor, increased glucose uptake and lactate production in MCF-7 and HepG2 cells (Zakikhani 
et al. 2012). KU-55933 also decreased levels of TCA metabolites fumarate, malate, citrate, and 
α-ketoglutarate in MCF-7 cells, while increasing succinate levels in those cells (Zakikhani et al. 
2012). Collectively, these results place ATM as a critical player in cellular energy metabolism.     
 
Specific Aims 
The overall goal of this study was to determine the role of ATM in cardiac autophagy and 
glucose metabolism under ischemic conditions. The specific aims of this study were to: (1) 
investigate the role of ATM deficiency in autophagy early (4 hours) during MI; (2) examine the 
role of ATM deficiency in autophagy late (28 days) post-MI; and (3) determine the role of ATM 
deficiency in glucose metabolism post-ischemia.    
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Abstract 
Ataxia-telangiectasia mutated kinase (ATM) is activated in response to DNA damage. We have 
previously shown that ATM plays a critical role in myocyte apoptosis and cardiac remodeling 
following myocardial infarction (MI). Here, we tested the hypothesis that ATM deficiency 
results in autophagic impairment in the heart early during MI. MI was induced in wild-type (WT) 
and ATM heterozygous knockout (hKO) mice by ligation of the left anterior descending artery 
(LAD). Structural and biochemical parameters of the heart were measured 4 hours following 
LAD ligation. M-mode echocardiography revealed that MI worsens heart function as evidenced 
by reduced percent ejection fraction and fractional shortening in both groups. However, MI-
induced increase in left ventricular end-diastolic and systolic diameters, and volumes were 
significantly lower in hKO hearts. ATM deficiency resulted in autophagic impairment during MI 
as evidenced by decreased LC3-II, increased p62, decreased cathepsin D protein levels, and 
increased aggresome accumulation. ERK1/2 activation was only observed in WT-MI hearts. 
Activation of Akt and AMPK was lower, whereas activation of GSK-3β and mTOR was higher 
hKO-MI hearts. Inhibition of ATM using KU-55933 resulted in autophagy impairment in cardiac 
fibroblasts as evidenced by decreased LC3-II protein levels and formation of acidic vesicular 
organelles. This impairment associated with decreased activation of Akt and AMPK, but 
enhanced activation of GSK-3β and mTOR in KU-treated fibroblasts. Thus, ATM deficiency 
results in autophagic impairment in the heart during MI and cardiac fibroblasts. This autophagic 
impairment may occur via the activation of GSK-3β and mTOR, and inactivation of Akt and 
AMPK.  
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New & Noteworthy 
ATM plays a critical role in myocyte apoptosis and cardiac remodeling following myocardial 
infarction (MI). Here, we provide evidence that ATM deficiency results in autophagic 
impairment during MI. Further investigation of the role of ATM in autophagy post-MI may 
provide novel therapeutic targets for Ataxia-telangiectasia patients suffering from heart disease.  
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Introduction 
Heart failure is the leading cause of death worldwide. Cardiovascular disease accounted 
for ~17.3 million deaths out of 54 million total deaths worldwide in 2013. Despite having 
medications to manage the complications of heart failure, there is currently no treatment to 
alleviate the condition (18). Coronary artery disease (CAD) is the most common form of heart 
disease with myocardial infarction (MI) as a serious outcome. Treatment of CAD and its 
progression to heart failure remains a challenging area of research (17). 
Ataxia-telangiectasia mutated kinase (ATM) is a ~370 kDa serine/threonine kinase that 
primarily resides in the nucleus (19, 20, 40, 44, 45, 54). The main function of ATM is to control 
cell cycle progression following DNA damage, particularly double strand breaks (1, 36). In 
response to DNA damage, ATM is activated and recruited to DNA double strand breaks. 
Although ATM has mostly been reported as a nuclear protein involved in signaling pathways 
that control DNA damage recognition, it is also located in the cytoplasm where it plays a role in 
several metabolic pathways (50, 54). Mutations in ATM cause a multisystemic disease known as 
Ataxia-telangiectasia (AT) (20, 40, 54). AT heterozygotes, individuals with an ATM mutation in 
one allele, make up a substantial portion of the population (~1.4 to 2%) (25, 30). The incidence 
of AT is significantly higher in consanguineous populations (6). Although AT heterozygotes are 
spared from most of the symptoms of AT, they are more susceptible to ischemic heart disease 
(25, 30).    
Macroautophagy (hereafter called autophagy) is a conserved physiological process in the 
body that ultimately results in the packaging of cytoplasmic components into autophagosomes 
that fuse to lysosomes for degradation (5, 23, 29, 37). Autophagy consist of three main phases: 1) 
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induction and phagophore formation, 2) phagophore elongation and autophagosome formation, 
and 3) lysosomal fusion, degradation, and recycling (38). Autophagy is critical to cellular 
homeostasis under normal and stressful conditions, and plays a crucial role in the development of 
diseases such as cancer and heart failure (5, 23, 37). In fact, autophagy is suggested to play a 
significant role in cardiac remodeling during MI. Studies have shown that autophagy promotes 
the survival of cardiac myocytes, reduces infarct size, and attenuates adverse cardiac remodeling 
post-MI (24, 52). Moreover, defects in autophagy have been linked to cardiac dysfunction and 
heart failure (22). Thus, autophagy is considered cardioprotective and a potential therapeutic 
target for the treatment of heart disease.  
Autophagic changes occur in mouse heart as early as 30 minutes following ligation of the 
left anterior descending artery (LAD). The LC3II-to-LC3-I ratio, an established indicator of 
autophagic turnover, is maximum 4 hours following LAD ligation (24), suggesting that 
autophagic activity increases in the ischemic heart during the early stages of MI. Previously we 
have shown that ATM plays a critical role in myocyte apoptosis and cardiac remodeling 
following β-adrenergic receptor stimulation and MI (10, 11, 14–16). Here, we tested the 
hypothesis that deficiency of ATM impairs autophagic response in the heart early during MI (4 
hours after its onset). The data presented here suggest that ATM deficiency impairs autophagy in 
the heart during MI via the activation of GSK-3β and mTOR, and inactivation of Akt and 
AMPK. 
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Materials and Methods 
Vertebrate Animals  
This investigation conforms to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). All 
the experiments were performed in accordance with the protocols approved by the East 
Tennessee State University Committee on Animal Care. ATM deficient mice (129xblack Swiss 
hybrid background), generated as described (4), were purchased from Jackson Laboratory. 
Genotyping was performed by PCR using primers suggested by the Jackson Laboratory. Age-
matched (~ 4-month-old) male and female mice were used for the study. Since homozygous 
knockout mice die at approximately 2 months of age due to thymic lymphomas (4), the study 
used ATM heterozygous knockout (hKO; deficient) mice. All mice undergoing surgery (Sham 
and MI) received buprenorphine injections prior to surgery.  
Myocardial Infarction 
Myocardial infarction (MI) was performed as previously described (10). Briefly, mice 
were anesthetized with a mixture of isoflurane (2%) and oxygen (0.5 l/min) inhalation and 
ventilated using a rodent ventilator (Harvard Apparatus). Body temperature was maintained at 
∼37°C using a heating pad. The heart was exposed by a left thoracotomy. The left anterior 
descending coronary artery (LAD) was ligated using a 7-0 polypropylene suture. Sham-operated 
mice underwent the same procedure without ligation of the LAD. At the end of the study period 
(4 hours following LAD ligation), isolated hearts were used for either histology or molecular 
analyses.  
30 
 
Echocardiography 
M-mode echocardiography images were obtained using transthoracic short-axis view 
imaging at midpapillary level 4 hours during MI using a Vevo 1100 machine utilizing a 550D 
probe. M-mode tracings were used to calculate percent fractional shortening (%FS) and ejection 
fractions (%EF) and measure heart rate, LV wall thicknesses, end-systolic (LVESD) and end-
diastolic dimensions (LVEDD), and end-systolic (LVESV) and end-diastolic volumes 
(LVEDV). An individual blinded to the experimental groups recorded the images, while a 
second individual assessed the images and calculated the structural and functional parameters of 
the heart.  
Aggresome detection by histological staining 
Paraffin-embedded heart sections were deparaffinized and rehydrated prior to staining. 
The tissue sections were immersed in xylene to remove the paraffin. Subsequently, the sections 
were rehydrated with decreasing ethanol concentrations (100, 90, 80%). The sections were 
stained using Proteostat dye (2000x dilution in PBS from the Proteostat Aggresomes Detection 
Kit, Enzo) for 3 minutes. The tissue sections were then washed in deionized water and destained 
using 1% acetic acid for 20 minutes. After washing with deionized water and PBS, slides were 
mounted using anti-fade mounting media, and visualized using the EVOS FL Auto fluorescence 
microscope (ThermoFisher Scientific). The images were acquired at 20x magnification. The 
number of aggresomes were quantified in the entire LV area.  
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Western blot analysis  
LV or cell lysates were prepared in RIPA buffer [10 mM Tris·HCl (pH 7.2), 158 mM 
NaCl, 1 mM EGTA, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 1 mM sodium 
orthovanadate, and 0.2 mM phenylmethylsulfonyl fluoride] supplemented with protease 
inhibitors. Equal amounts of proteins (25 μg) were resolved using SDS-PAGE. The proteins 
were then transferred to a PVDF membrane. The membrane was blocked for one hour using 5% 
nonfat milk and incubated overnight with primary antibodies against LC3B (1:1000), p62 
(1:1000), p-Akt (ser-473; 1:1000), p-GSK-3β (ser-9; 1:1000), p-mTOR (ser-2448; 1:1000), p-
ERK1/2 (1:1000) (Cell Signaling), cathepsin D (1:1000), or p-AMPK (thr-172; 1:1000) (Santa 
Cruz). The immune-complexes were detected using appropriate secondary antibodies and 
chemiluminescent reagents. Protein signals were visualized using ImageQuant LAS 500 imager 
and quantified using ImageQuant TL software (GE). Equal protein loading for phosphoproteins 
was verified by reprobing/probing the membranes using anti-Akt, anti-GSK-3β, anti-AMPK, 
anti-mTOR, anti-ERK1/2 and anti-GAPDH antibodies. Quantitative analyses showed no 
differences in total protein levels for these proteins among the groups. Therefore, all the western 
blot data is normalized using GAPDH as a loading control.   
Fibroblast isolation and treatment 
Adult rat cardiac fibroblasts were isolated as previously described (53). The cells were 
grown to confluence in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
heat-inactivated fetal bovine serum and serum starved for 5 hours before use. The cells were then 
treated with the ATM inhibitor KU-55933 (KU; 100 μM; Tocris) for 4 hours. The cells were 
maintained in serum-free DMEM for the duration of the treatment.  
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Evaluation of acidic vesicular organelles by acridine orange 
At the end of the study period, fibroblasts treated with KU for 4 hours were incubated 
with 1 μg/mL acridine orange (Sigma) in serum-free DMEM for 15 minutes. The cells were then 
washed three times using PBS and observed using the EVOS FL Auto fluorescence microscope 
(ThermoFisher Scientific). All images were acquired at 20x magnification. Occurrence of acidic 
vesicular organelles was measured by the intensity of orange fluorescence using NIS-Elements 
image analysis software (Nikon). Aggresomes were quantified by counting cells in 15 randomly 
chosen fields per dish for each experiment.  
Statistical analysis 
Data are expressed as means ± SE. Data were analyzed using Student's t-test or a two-
way analysis of variance followed by the Student-Newman-Keuls test. P values of <0.05 were 
considered to be significant. 
Results 
Echocardiographic measurements 
M-mode echocardiography showed no difference in echocardiographic parameters 
between the two sham groups. MI significantly decreased %EF (WT-sham, 59.26±2.39; hKO-
sham, 61.09±2.43; WT-MI, 31.59±5.75*; hKO-MI, 26.95±5.16*; *p<0.05 vs. respective sham; 
n=5) and FS (WT-sham, 30.96±1.66; hKO-sham, 32.17±1.69; WT-MI, 14.95±2.97*; hKO-MI, 
12.29±2.69*; *p<0.05 vs. respective sham; n=5) in both groups compared to their respective 
shams. However, there was no significant difference in %EF and FS between the two genotypes 
post-MI (Figure 2.1A-2.1B). MI increased LVEDD (WT-sham, 3.19±0.17; hKO-sham, 
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3.36±0.33; WT-MI, 3.62±0.10*; hKO-MI, 3.07±0.16#; *p˂0.05 vs respective sham; #p˂0.05 vs 
WT-MI; n=5), LVESD (WT-sham, 2.21±0.13; hKO-sham, 2.30±0.26; WT-MI, 3.09±0.18*; 
hKO-MI, 2.65±0.14#; *p˂0.05 vs respective sham; #p˂0.05 vs WT-MI; n=5), LVEDV (WT-
sham, 41.70±4.76; hKO-sham, 49.10±10.67; WT-MI, 55.67±3.47*; hKO-MI, 38.41±5.02#; 
*p˂0.05 vs respective sham; #p˂0.05 vs WT-MI; n=5), and LVESV (WT-sham, 17.06±2.30; 
hKO-sham, 19.90±4.85; WT-MI, 36.68±5.41*; hKO-MI, 26.44±3.42#; *p˂0.05 vs respective 
sham; #p˂0.05 vs WT-MI; n=5) in WT when compared to WT-sham group. However, there was 
no significant increase in LVEDD, LVESD, LVEDV, and LVESV in hKO-MI versus hKO-sham 
group. In fact, these parameters were significantly lower in the hKO-MI versus WT-MI group 
(Figure 2.1C-2.1F). Heart rates, and posterior and septal wall thicknesses were not found to be 
significantly different between the two MI groups (data not shown).  
34 
 
 
 
 
Expression of autophagy-related proteins in cardiac tissue  
LC3 is considered as one of the most important autophagy markers since it is essential to 
autophagosome formation (39). In mammalian cells, LC3 is processed into LC3-I, a soluble form 
of LC3. LC3-I is then modified to LC3-II, a membrane-bound form of LC3, by the addition of 
Figure 2.1. Echocardiographic analysis of heart function. MI was performed in WT and hKO 
mice. Indices of cardiac function; percent ejection fraction (%EF), percent fractional 
shortening (%FS), LVEDD, LVESD, LVEDV, and LVESV were calculated using 
echocardiographic images 4 hours following LAD ligation. A: %EF. B: %FS. C: LVEDD. D: 
LVESD. E: LVEDV. F: LVESV. *p˂0.05 vs respective sham; #p˂0.05 vs WT-MI; n=5. 
LVEDD, LV end-diastolic diameter; LVESD, LV end-systolic diameter; LVEDV, LV end-
diastolic volume; LVESV, LV end-systolic volume.  
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phosphatidylethanolamine (PE). To date, LC3-II is the only well-characterized protein that is 
specifically localized to autophagosomes throughout the autophagy process, from 
autophagosome formation to lysosomal degradation. Thus, measuring the levels of LC3-II 
protein is suggested to be a good marker for early autophagosome formation (39). Western blot 
analysis of LV lysates using an anti-LC3 antibody revealed a significant increase in LC3-II 
protein levels in hKO-sham versus the WT-sham group (Figure 2.2). LC3-II protein levels were 
significantly increased in the WT-MI group when compared to the WT-sham. In contrast, LC3-II 
protein levels were significantly lower in the hKO-MI group when compared to the hKO-sham 
and WT-MI groups (*p˂0.05 vs respective sham; #p˂0.05 vs WT-MI; n=4-7; Figure 2.2).  
 
Figure 2.2. ATM deficiency reduces LC3-II protein levels 4 hours during MI. Total LV 
lysates, prepared from sham and MI hearts, were analyzed by western blot using LC3B 
antibodies. Top: western blot exhibiting immunostaining for LC3-I, LC3-II and GAPDH. 
Bottom: quantitative analysis of LC3-II normalized to GAPDH (*p˂0.05 vs respective sham; 
#p˂0.05 vs WT-MI; n=4-7).  
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p62 is an autophagy receptor, meaning that it recognizes and transports misfolded 
proteins to the autophagosome for degradation by lysosomes (33). Cathepsin D, a lysosomal 
protease, is involved in lysosomal degradation of misfolded proteins (49). Both p62 and 
cathepsin D are critical to autophagic clearance or the degradation of autophagolysosomes. p62 
protein levels were significantly higher in the hKO-sham group when compared to its WT 
counterpart (Figure 2.3A). p62 protein levels remained unchanged in WT-MI group. However, 
p62 protein levels were significantly greater in hKO-MI group versus the hKO-sham and WT-MI 
groups (*p˂0.05 vs respective sham; #p˂0.05 vs WT-MI; n=5-7; Figure 2.3A). Cathepsin D 
protein levels were not significantly different between the two sham groups. Cathepsin D protein 
levels remained unchanged in WT-MI group. However, MI led to a significant decrease in 
cathepsin D levels in hKO group versus hKO-sham and WT-MI groups (*p˂0.05 vs respective 
sham; #p˂0.05 vs WT-MI; n=4-5; Figure 2.3B).  
 
 
Figure 2.3. ATM deficiency increases p62 protein levels and decreases cathepsin D protein 
levels 4 hours during MI. Total LV lysates, prepared from sham and MI hearts, were analyzed by 
western blot using anti-p62 (A) and anti-cathepsin D (B) antibodies. Both p62 bands were 
analyzed. Top: western blots exhibiting immunostaining for p62, cathepsin D, and GAPDH. 
Bottom: quantitative analyses of p62 and cathepsin D protein levels normalized to GAPDH 
(*p˂0.05 vs respective sham; #p˂0.05 vs WT-MI; n=4-7). 
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Activation of signaling molecules related to autophagy 
Typically, Akt signaling acts as a positive regulator of autophagy (47). However, there 
are several downstream targets of Akt, such as GSK-3β, AMPK, and mTOR, that can act to 
either upregulate or downregulate the autophagy pathway. Inactivation (phosphorylation) of 
GSK-3β induces autophagy (7, 35, 51), while activation (phosphorylation) of AMPK stimulates 
autophagy (27) and activation (phosphorylation) of mTOR inhibits autophagy (27, 28). 
Phosphorylation of Akt remained unchanged in the sham groups and in the WT group post-MI. 
However, phosphorylation of Akt was significantly lower in the hKO-MI group when compared 
to hKO-sham and WT-MI groups (*p˂0.05 vs respective sham; #p˂0.05 vs WT-MI; n=5-7; 
Figure 2.4A). Akt acts as an upstream regulator of GSK-3β, phosphorylating it at serine 9 and 
inactivating it (13). Phosphorylation of GSK-3β was significantly lower in the hKO-MI group 
when compared to hKO-sham and WT-MI groups (*p˂0.05 vs respective sham; #p˂0.05 vs WT-
MI; n=5-7; Figure 2.4B). AMPK phosphorylation was significantly lower in the hKO-MI group 
when compared to hKO-sham and WT-MI groups (*p˂0.05 vs respective sham; #p˂0.05 vs WT-
MI; n=5-7; Figure 2.4C). mTOR phosphorylation was significantly lower in hKO-sham vs WT-
sham. MI significantly increased mTOR phosphorylation in both genotypes versus their 
respective sham groups. However, phosphorylation of mTOR was significantly greater in hKO-
MI when compared to WT-MI group (*p˂0.05 vs respective sham; #p˂0.05 vs WT-MI; n=4-5; 
Figure 2.4D).  
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ERK1/2 activation acts as a positive regulator of autophagy (47). ERK1/2 
phosphorylation was not significantly different between the two sham groups. ERK1/2 
phosphorylation was significantly higher in the WT-MI compared to the WT-sham group 
(*p˂0.05 vs respective sham; #p˂0.05 vs WT-MI; n=7; Figure 2.5). It remained unchanged 
between the hKO-MI vs hKO-sham group.   
 
Figure 2.4. ATM deficiency affects activation of Akt, GSK-3β, AMPK, and mTOR 4 hours 
during MI. Total LV lysates, prepared from sham and MI hearts, were analyzed by western 
blot using anti-p-Akt (A), anti-p-GSK-3β (B), anti-p-AMPK (C), and anti-p-mTOR (D) 
antibodies. Top: western blots exhibiting immunostaining for p-Akt, p-GSK-3β, p-AMPK, p-
mTOR, and GAPDH. Bottom: quantitative analyses of p-Akt, p-GSK-3β, p-AMPK, and p-
mTOR normalized to GAPDH (*p˂0.05 vs respective sham; #p˂0.05 vs WT-MI; n=4-7).   
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Aggresome formation in cardiac tissue  
Aggresomes are aggregates of misfolded proteins within cells, which can ultimately be 
degraded by the autophagy pathway (46). The number of aggresomes was significantly lower in 
hKO-sham when compared to WT-sham group. MI led to decreased number of aggresomes in 
WT-MI versus WT-sham group. However, the number of aggresomes was significantly higher in 
hKO-MI group when compared to hKO-sham and WT-MI groups (*p˂0.05 vs respective sham; 
#p˂0.05 vs WT-MI; n=3; Figure 2.6).  
 
 
Figure 2.5. ERK1/2 activation 4 hours during MI. Total LV lysates, prepared from sham and 
MI hearts, were analyzed by western blot using phospho-specific ERK1/2 antibodies. Top: 
western blot exhibiting immunostaining for p-ERK1/2 and GAPDH. Bottom: quantitative 
analysis of p-ERK1/2 normalized to GAPDH (*p˂0.05 vs respective sham; n=7).   
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Autophagic response in cardiac fibroblasts  
Cardiac fibroblast-specific deletion of ATM in mice is shown to play a pivotal role in 
doxorubicin-induced cardiotoxicity (55). In fact, cardiac fibroblasts serve as a major cell type 
involved in deposition of fibrosis in the heart post-MI (48). To investigate if inhibition of ATM 
affects autophagic response of cardiac fibroblasts, serum-starved cultures of cardiac fibroblasts 
were treated with KU (100 μM) for 4 hours. Western blot analyses of cell lysates showed a 
significant decrease in LC3-II protein levels in KU-treated cells (*p˂0.05 vs CTL; n=3; Figure 
2.7). ATM inhibition had no effect on p62 and cathepsin D protein levels (data not shown).  
Figure 2.6. ATM increases aggresome accumulation in the LV 4 hours during MI. Left: 
Proteostat dye-stained images obtained from the LV of WT and hKO hearts 4 hours during 
MI. Red fluorescent staining indicates aggresomes. Right: quantitative analysis of aggresomes 
in the LV region (*p˂0.05 vs respective sham; #p˂0.05 vs WT-MI; n=3). 
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KU treatment significantly decreased phosphorylation of Akt, GSK-3β, and AMPK 
(*p˂0.05 vs CTL; n=3; Figure 2.8A-2.8C). However, it significantly increased mTOR 
phosphorylation (*p˂0.05 vs CTL; n=3; Figure 2.8D).  
Figure 2.7. Inhibition of ATM reduces LC3-II protein levels in cardiac fibroblasts. Serum-
starved cardiac fibroblasts were treated with KU-55933 (100 µm; ATM inhibitor) for 4 hours. 
Total cell lysates were analyzed by western blot using LC3B antibodies. Top: western blot 
exhibiting immunostaining for LC3-I, LC3-II and GAPDH. Bottom: quantitative analysis of 
LC3-II normalized to GAPDH (*p˂0.05 vs CTL; n=3). 
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The formation of acidic vesicular organelles (AVOs) is a key characteristic of cells that 
have passed through autophagy. AVOs, such as autolysosomes, increase upon autophagy 
induction (43). KU significantly decreased AVO formation in cardiac fibroblasts 4 hours post-
treatment (*p˂0.05 vs CTL; n=3; Figure 2.9). 
Figure 2.8. Inhibition of ATM affects activation of Akt, GSK-3β, AMPK, and mTOR in 
cardiac fibroblasts. Serum-starved cardiac fibroblasts were treated with KU-55933 (100 µm; 
ATM inhibitor) for 4 hours. Total cell lysates were analyzed by western blot using anti-p-Akt 
(A), anti-p-GSK-3β (B), anti-p-AMPK (C), and anti-p-mTOR (D) antibodies. Top: western 
blots exhibiting immunostaining for p-Akt, p-GSK-3β, p-AMPK, p-mTOR, and GAPDH. 
Bottom: quantitative analyses of p-Akt, p-GSK-3β, p-AMPK, and p-mTOR normalized to 
GAPDH (*p˂0.05 vs CTL; n=3). 
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Discussion 
ATM typically becomes activated in the presence of double-stranded DNA breaks (1, 
36). Thus, most of the studies regarding ATM and autophagy have been in relation to the DNA 
damage response. This is the first study investigating the role of ATM in cardiac autophagy, 
particularly during MI. A major finding of this study is that ATM deficiency results in 
autophagic impairment 4 hours during MI. This is evidenced by decreased LC3-II, increased 
p62, decreased cathepsin D protein levels, and enhanced aggresome accumulation. In accordance 
with in vivo data, ATM inhibition also resulted in autophagic impairment in adult cardiac 
Figure 2.9. Inhibition of ATM decreases acidic vesicular organelle (AVOs) formation in cardiac 
fibroblasts. Cardiac fibroblasts were treated with KU-55933 (100 µm) for 4 hours and then 
stained with acridine orange dye. Left: Orange fluorescent staining indicates acidic vesicular 
organelles (AVOs). Right: quantitative analysis of acidic vesicular organelles (AVOs) in cardiac 
fibroblasts (*p˂0.05 vs CTL; n=3).   
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fibroblasts as shown by a reduction in LC3-II protein expression and decrease in acidic vesicular 
organelle (AVO) formation. Further, we provide evidence that ATM deficiency may exert its 
effect on autophagy during MI via the activation of GSK-3β and mTOR and inactivation of Akt 
and AMPK as phosphorylation of Akt, GSK-3β, and AMPK decreased during MI, while mTOR 
phosphorylation increased during MI.  
MI worsened heart function 4 hours during MI as evidence by a decrease in %EF and FS 
in both groups when compared to their respective sham group. This is consistent with the 
observations of de Andrade et al. (2015) in CD1 mice where MI led to decreased %EF and FS 4 
hours following LAD ligation (3). Previously we provided evidence that ATM deficiency 
improves left ventricular (LV) function 1 day following LAD ligation as observed by hKO-MI 
hearts exhibiting higher %EF and FS coupled with lower LVESV and LVEDV when compared 
to WT-MI group (10). Here, %EF and FS remained unchanged between the two MI groups 4 
hours following LAD ligation. The observed no significant difference in %EF and FS between 
WT and hKO hearts may relate to an early observation time point (4 hours vs 24 hours after 
LAD ligation).    
Autophagy is suggested to be cardioprotective, reducing infarct size and attenuating 
adverse cardiac remodeling post-MI (24, 52). Moreover, defects in autophagy have been linked 
to cardiac dysfunction and heart failure (22). Thus, autophagy is typically upregulated post-MI 
(2, 24, 52). Specifically autophagy is induced in the acute phase of MI but impaired in the later 
phase of MI (24, 52). However, the mechanism(s) by which these autophagic changes occur 
post-MI is unknown. In our study, MI resulted in autophagic induction early during MI in WT 
hearts as evidenced by high LC3-II protein levels coupled with reduced aggregate accumulation. 
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Interestingly, Akt, GSK-3β, and AMPK phosphorylation was unaffected in WT hearts during 
MI. However, phosphorylation of mTOR (activation) and activation of ERK1/2 were 
significantly higher in WT hearts during MI. Several studies suggest that ERK1/2 signaling 
positively regulates autophagy (21, 47, 57). However, the involvement of mTOR in ERK1/2-
mediated autophagic changes are not completely clear. Zhang et al. showed that mTOR 
inhibition results in ERK1/2 activation that induces autophagy in hepatocellular carcinoma (56). 
Choi et al. demonstrated that ERK1/2 activation induced autophagy in luteal cells independent of 
mTOR activation (9). Additionally, ERK1/2 activation results in autophagic impairment in 
irinotecan-induced steatohepatitis (34). In the current study, we provide evidence that ERK1/2 
activation may be involved in the induction of autophagy in WT hearts during MI. However, 
further investigations are needed to define the correlation between ERK1/2 and mTOR 
activation.  
ATM is suggested to play a role in autophagy, particularly following DNA damage in 
cancer models. ATM is shown to be necessary for autophagy induction in response to ionizing 
radiation in Hela cells, a human cervical cancer cell line (32). ATM-mediated phosphorylation of 
PTEN promoted autophagy in cancer cells in response to DNA-damage causing agents (8). 
ATM/AMPK  signaling promoted autophagy induction in mouse spermatocytes in response to 
cadmium-induced oxidative stress (31). In the present study, we provide evidence that ATM is 
critical in cardiac autophagy at basal levels and during MI. ATM deficiency induces autophagy 
at basal levels as indicated by increased LC3-II protein levels coupled with an accumulation of 
p62. However, the number of aggresomes were lower in hKO-sham versus WT-sham group. 
Thus, it is possible that under basal conditions ATM deficiency results in enhanced autophagic 
flux; such enhancement could result in the accumulation of LC3-II and p62 and the rapid 
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degradation of aggresomes. During MI, ATM deficiency resulted in reduced LC3-II, increased 
p62, decreased cathepsin D protein levels and enhanced aggresome accumulation. Similarly, 
ATM inhibition resulted in a reduction in the LC3-II protein levels in cardiac fibroblasts. 
Although inhibition of ATM had no effect on p62 and cathepsin D protein expression in cardiac 
fibroblasts, the formation of acidic vesicular organelles was reduced. Together, these results 
suggest that ATM deficiency impairs autophagy in the heart at all three stages (autophagy 
induction, autophagosome formation, and autophagolysosome degradation) during MI and in 
cardiac fibroblasts. In ATM deficient hearts during MI, initiation of autophagy is lower as 
evidenced by decreased LC3-II. The enhanced accumulation of p62 and aggresomes is likely due 
to decreased cathepsin D levels, indicating impairment in aggresome degradation. In KU-treated 
cardiac fibroblasts, initiation of autophagy is decreased as evidenced by decreased LC3-II levels. 
The decrease in acidic vesicular organelles coupled with no changes in p62 and cathepsin D 
suggests a lack of autophagosome formation and subsequent degradation. Thus ATM deficiency 
impairs autophagy in the heart during MI and in cardiac fibroblasts by inhibiting autophagy 
induction, autophagosome formation, and autophagolysosome degradation. These findings 
ultimately reveal that ATM is critical in cardiac autophagy regulation in the presence and 
absence of an insult.     
The Akt/GSK-3β pathway is well known as a pro-survival pathway as it typically 
prevents apoptotic signaling (12). Akt signaling has also been implicated in the regulation of 
autophagy. Akt activation induces autophagy in the brain following middle cerebral artery 
occlusion, resulting in neuroprotection (42). Pharmacological inhibition of GSK-3β induces pro-
survival autophagic signals in human pancreatic cancer cells (35). Additionally, knockdown of 
GSK-3β increases basal autophagy and AMPK signaling in human aortic endothelial cells (51). 
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AMPK functions as an energy sensor in cells that is activated by ATP depletion or glucose 
starvation (41). In the heart, AMPK activation is critical to the heart’s response to stresses such 
as ischemia (41). Pharmacological activation of AMPK has cardioprotective effects, protecting 
the heart against ischemia-reperfusion injury by maintaining ATP levels post ischemia and 
reducing infarct size (26). AMPK activation promotes autophagy (27). Under conditions of low 
energy levels and hypoxia, AMPK inhibits mTOR (the master regulator of autophagy) activity 
via the phosphorylation of Raptor (7, 28). In the present study, we provide evidence that 
autophagic enhancement during ATM deficiency under basal conditions does not involve 
alterations in Akt, GSK-3β, or AMPK phosphorylation as those parameters remained unchanged 
in ATM deficient hearts. However, mTOR phosphorylation was lower in ATM deficient hearts, 
indicating that enhanced autophagic response in ATM deficient hearts under basal conditions 
may be mTOR dependent. ATM deficiency may cause autophagic impairment during MI and in 
cardiac fibroblasts via the activation of GSK-3β and mTOR, and inactivation of Akt and AMPK. 
We suggest that inactivation of Akt causes a reduction in GSK-3β phosphorylation, thus 
activating GSK-3β. Increased GSK-3β activity may result in a decline in AMPK phosphorylation 
and activation. This decline in AMPK activation results in mTOR activation that ultimately 
inhibits autophagic response. However, further investigations are necessary to confirm the 
relationship between the activation of GSK-3β and mTOR, and inactivation of Akt and AMPK in 
regulating autophagy during MI in ATM deficient hearts.     
In summary, WT hearts exhibited autophagy induction during MI, a phenomenon most 
likely because ERK1/2 activation. Under basal conditions, ATM deficiency results in enhanced 
autophagic response that appears to be mTOR dependent. In addition, ATM deficiency results 
autophagic impairment in all phases (autophagy induction, autophagosome formation, and 
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autophagolysosome degradation) during MI and in cardiac fibroblasts via the activation of GSK-
3β and mTOR, and inactivation of Akt and AMPK. It should be emphasized that our data on 
ATM deficiency and cardiac autophagy are obtained 4 hours following LAD ligation. The 
experimental time point should be extended beyond 4 hours to investigate the long-term effects 
of ATM deficiency on autophagic changes in the heart.  
Acknowledgements 
Technical help received from Barbara A. Connelly is appreciated. 
Funding 
This work was supported by Merit Review awards (BX002332 and BX000640) from the 
Biomedical Laboratory Research and Development Service of the Veterans Affairs Office of 
Research and Development, National Institutes of Health (R15HL129140), and funds from 
Institutional Research and Improvement account (to KS) and C06RR0306551. 
Disclosures 
No conflicts of interest, financial or otherwise, are declared by the authors. 
Author Contributions 
P.R.T., M.S., and K.S. conception and design of research; P.R.T., S.L.S., C.C.C., and S.D. 
performed experiments; P.R.T., S.L.S., and C.C.C. analyzed data; P.R.T. and K.S. interpreted 
results of experiments; P.R.T. prepared figures; P.R.T. drafted manuscript; P.R.T., M.S., and 
49 
 
K.S. edited and revised manuscript; P.R.T., S.L.S., S.D., C.C.C., M.S., and K.S. approved final 
version of manuscript.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
References 
1.  Abraham RT. cell cycle checkpoint signaling therough the ATM an ATR kinases. Genes 
Dev 15: 2177–2196, 2001. 
2.  Aisa Z, Liao GC, Shen XL, Chen J, Li L, Jiang SB. Effect of autophagy on myocardial 
infarction and its mechanism. Eur Rev Med Pharmacol Sci 21: 3705–3713, 2017.  
3.  de Andrade JNBM, Tang J, Hensley MT, Vandergriff A, Cores J, Henry E, Allen TA, 
Caranasos TG, Wang Z, Zhang T, Zhang J, Cheng K. Rapid and efficient production of 
coronary artery ligation and myocardial infarction in mice using surgical clips. PLoS One 
10: e0143221, 2015. 
4.  Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, Shiloh Y, Crawley 
JN, Ried T, Tagle D, Wynshaw-Boris A. Atm - deficient mice : a paradigm of ataxia 
telangiectasia. Cell 86: 159–171, 1996. 
5.  Bravo-San Pedro JM, Kroemer G, Galluzzi L. Autophagy and mitophagy in 
cardiovascular disease. Circ Res 120: 1812–1824, 2017. 
6.  Broides A, Nahum A, Mandola AB, Rozner L, Pinsk V, Ling G, Yerushalmi B, Levy J, 
Givon-Lavi N. Incidence of typically severe primary immunodeficiency diseases in 
consanguineous and non-consanguineous populations. J Clin Immunol 37: 295–300, 2017. 
7.  Chang HJ, Seung-Hyun R, Jing C, Neil MO, Kim DH. mTOR regulation of autophagy. 
FEBS Lett 584: 1287–1295, 2010. 
8.  Chen JH, Zhang P, Chen WD, Li DD, Wu XQ, Deng R, Jiao L, Li X, Ji J, Feng GK, Zeng 
YX, Jiang JW, Zhu XF. ATM-mediated PTEN phosphorylation promotes PTEN nuclear 
translocation and autophagy in response to DNA-damaging agents in cancer cells. 
Autophagy 11: 239–252, 2015. 
9.  Choi JY, Jo MW, Lee EY, Choi DS. ERK1/2 is involved in luteal cell autophagy 
regulation during corpus luteum regression via an mTOR-independent pathway. Mol Hum 
Reprod 20: 972–980, 2014. 
10.  Daniel LL, Daniels CR, Harirforoosh S, Foster CR, Singh M, Singh K. Deficiency of 
ataxia telangiectasia mutated kinase delays inflammatory response in the heart following 
myocardial infarction. J Am Heart Assoc 3: 1–12, 2014. 
11.  Daniel LL, Scofield SLC, Thrasher P, Dalal S, Daniels CR, Foster CR, Singh M, Singh K. 
Ataxia telangiectasia-mutated kinase deficiency exacerbates left ventricular dysfunction 
and remodeling late after myocardial infarction. Am J Physiol - Hear Circ Physiol 311: 
H445–H452, 2016. 
12.  Endo H, Nito C, Kamada H, Nishi T, Chan PH. Activation of the Akt/GSK3β signaling 
pathway mediates survival of vulnerable hippocampal neurons after transient global 
cerebral ischemia in rats. J Cereb Blood Flow Metab 26: 1479–1489, 2006. 
13.  Fang X, Yu SX, Lu Y, Bast RC, Woodgett JR, Mills GB. Phosphorylation and 
inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 
97: 11960–11965, 2000. 
14.  Foster CR, Daniel LL, Daniels CR, Dalal S, Singh M, Singh K. Deficiency of ataxia 
telangiectasia mutated kinase modulates cardiac remodeling following myocardial 
51 
 
infarction: involvement in fibrosis and apoptosis. PLoS One 8: 1–11, 2013. 
15.  Foster CR, Singh M, Subramanian V, Singh K. Ataxia telangiectasia mutated kinase plays 
a protective role in β-adrenergic receptor-stimulated cardiac myocyte apoptosis and 
myocardial remodeling. Mol cell Biochem 353: 13–22, 2011. 
16.  Foster CR, Zha Q, Daniel LL, Singh M, Singh K. Lack of ataxia telangiectasia mutated 
kinase induces structural and functional changes in the heart: role in β-adrenergic 
receptor-stimulated apoptosis. Exp Physiol 97: 506-515, 2012. 
17.  Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 58: 88–111, 
2008. 
18.  Benjamin EM, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd 
J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, 
Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, 
Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, 
Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson 
C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu 
JHY, Alger HM, Wong SS, Muntner P, American Heart Association Statistics Committee 
and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a 
report from the american heart association. Circulation 135: e1-e458, 2017. 
19.  Viniegra JG, Martínez N, Modirassari P, Hernández Losa J, Parada Cobo C, Sánchez-
Arévalo Lobo VJ, Aceves Luquero CI, Álvarez-Vallina L, Ramón Y Cajal S, Rojas JM, 
Sánchez-Prieto R. Full activation of PKB/Akt in response to insulin or ionizing radiation 
is mediated through ATM. J Biol Chem 280: 4029–4036, 2005. 
20.  Halaby MJ, Hibma JC, He J, Yang DQ. ATM protein kinase mediates full activation of 
Akt and regulates glucose transporter 4 translocation by insulin in muscle cells. Cell 
Signal 20: 1555–1563, 2008. 
21.  He C, Klionsky DJ. Regulation mechanisms and signalling pathways of autophagy. Annu 
Rev Genet 43: 67-93, 2009. 
22.  Ilkun O, Boudina S. Cardiac dysfunction and oxidative stress in the metabolic syndrome: 
an update on antioxidant therapies. Curr Pharm Des 19: 4806–17, 2013. 
23.  Jimenez RE, Kubli DA, Gustafsson ÅB. Autophagy and mitophagy in the myocardium: 
therapeutic potential and concerns. Br J Pharmacol 171: 1907–1916, 2014. 
24.  Kanamori H, Takemura G, Goto K, Maruyama R, Ono K, Nagao K, Tsujimoto A, Ogino 
A, Takeyama T, Kawaguchi T, Watanabe T, Kawasaki M, Fujiwara T, Fujiwara H, 
Seishima M, Minatoguchi S. Autophagy limits acute myocardial infarction induced by 
permanent coronary artery occlusion. Am J Physiol Heart Circ Physiol 300: H2261–
H2271, 2011. 
25.  Khanna KK, Lavin MF, Jackson SP, Mulhern TD. ATM, a central controller of cellular 
responses to DNA damage. Cell Death Differ 8: 1052–1065, 2001. 
26.  Kim AS, Miller EJ, Wright TM, Li J, Qi D, Atsina K, Zaha V, Sakamoto K, Young LH. A 
small molecule AMPK activator protects the heart against ischemia-reperfusion injury. J 
Mol Cell Cardiol 51: 24–32, 2011. 
27.  Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through 
52 
 
direct phosphorylation of Ulk1. Nat Cell Biol 13: 132–141, 2011. 
28.  Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest 
125: 25–32, 2015. 
29.  Klionsky DJ, Cuervo AM, Seglen PO. Methods for monitoring autophagy from yeast to 
human. Autophagy 3: 181–206, 2007. 
30.  Lavin MF, Khana KK, Beamish H, Spring K, Watters D, Shiloh Y. Relationship of the 
ataxia-telangiectasia protein ATM to phosphoinositide 3-kinase. Trends Biochem Sci 20: 
382–383, 1995. 
31.  Li R, Luo X, Zhu Y, Zhao L, Li L, Peng Q, Ma M, Gao Y. ATM signals to AMPK to 
promote autophagy and positively regulate DNA damage in response to cadmium-induced 
ROS in mouse spermatocytes. Environ. Pollut. 231: 1560-1568, 2017. (2017).  
32.  Liang N, Jia L, Liu Y, Liang B, Kong D, Yan M, Ma S, Liu X. ATM pathway is essential 
for ionizing radiation-induced autophagy. Cell Signal 25: 2530–2539, 2013. 
33.  Liu WJ, Ye L, Huang WF, Guo LJ, Xu ZG, Wu HL, Yang C, Liu HF. p62 links the 
autophagy pathway and the ubiqutin–proteasome system upon ubiquitinated protein 
degradation. Cell Mol Biol Lett 21: 21-29, 2016. 
34.  Mahli A, Saugspier M, Koch A, Sommer J, Dietrich P, Lee S, Thasler R, Schulze-
Luehrmann J, Luehrmann A, Thasler WE, Müller M, Bosserhoff A, Hellerbrand C. ERK 
activation and autophagy impairment are central mediators of irinotecan-induced 
steatohepatitis. Gut 0: 1–11, 2017. 
35.  Marchand B, Arsenault D, Raymond-Fleury A, Boisvert FM, Boucher MJ. Glycogen 
synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human 
pancreatic cancer cells. J Biol Chem 290: 5592–5605, 2015. 
36.  Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 
protein kinase. Science 282: 1893–1897, 1998. 
37.  Meijer AJ, Codogno P. Autophagy: regulation and role in disease. Crit Rev Clin Lab Sci 
46: 210–240, 2009. 
38.  Mizushima N. Autophagy : process and function. Genes Dev 21: 2861–2873, 2007. 
39.  Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 3: 542–
545, 2007. 
40.  Peretz S, Jensen R, Baserga R, Glazer PM. ATM-dependent expression of the insulin-like 
growth factor-I receptor in a pathway regulating radiation response. Proc Natl Acad Sci U 
S A 98: 1676–1681, 2001. 
41.  Qi D, Young LH. AMPK: energy sensor and survival mechanism in the ischemic heart. 
Trends Endocrinol Metab 26: 422–429, 2015. 
42.  Qi ZF, Luo YM, Liu XR, Wang RL, Zhao HP, Yan F, Song ZJ, Luo M, Ji XM. 
AKT/GSK3β-dependent autophagy contributes to the neuroprotection of limb remote 
ischemic postconditioning in the transient cerebral ischemic rat model. CNS Neurosci 
Ther 18: 965–973, 2012. 
43.  Rasul A, Yu B, Khan M, Zhang K, Iqbal F, Ma T, Yang H. Magnolol, a natural 
compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the 
53 
 
mitochondrial and PI3K/Akt signaling pathways. Int J Oncol 40: 1153–1161, 2012. 
44.  Rotman G, Shiloh Y. ATM : from gene to function. Hum Mol Genet 7: 1555–1563, 1998. 
45.  Schneider JG, Finck BN, Ren J, Standley KN, Takagi M, Maclean KH, Bernal-Mizrachi 
C, Muslin AJ, Kastan MB, Semenkovich CF. ATM-dependent suppression of stress 
signaling reduces vascular disease in metabolic syndrome. Cell Metab 4: 377–389, 2006. 
46.  Shen D, Coleman J, Chan E, Nicholson TP, Dai L, Sheppard PW, Patton WF. Novel cell- 
and tissue-based assays for detecting misfolded and aggregated protein accumulation 
within aggresomes and inclusion bodies. Cell Biochem Biophys 60: 173–185, 2011. 
47.  Sridharan S, Jain K, Basu A. Regulation of autophagy by kinases. Cancers (Basel) 3: 
2630–2654, 2011. 
48.  Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction—from repair and 
remodeling to regeneration. Cell Tissue Res 365: 563–581, 2016. 
49.  Tatti M, Motta M, Di Bartolomeo S, Scarpa S, Cianfanelli V, Cecconi F, Salvioli R. 
Reduced cathepsins B and D cause impaired autophagic degradation that can be almost 
completely restored by overexpression of these two proteases in Sap C-deficient 
fibroblasts. Hum Mol Genet 21: 5159–5173, 2012. 
50.  Watters D, Kedar P, Spring K, Bjorkman J, Chen P, Gatei M, Birrell G, Garrone B, 
Srinivasa P, Crane DI, Lavin MF. Localization of a portion of extranuclear ATM to 
peroxisomes. J Biol Chem 274: 34277–34282, 1999. 
51.  Weikel KA, Cacicedo M, Ruderman NB, Ido Y. Knockdown of GSK3 β increases basal 
autophagy and AMPK signalling in nutrient-laden human aortic endothelial cells. Biosci 
Rep 36: 1–16, 2016. 
52.  Wu X, He L, Chen F, He X, Cai Y, Zhang G, Yi Q, He M, Luo J. Impaired autophagy 
contributes to adverse cardiac remodeling in acute myocardial infarction. PLoS One 9: 1–
11, 2014. 
53.  Xie Z, Singh M, Singh K. Differential regulation of matrix metalloproteinase-2 and -9 
expression and activity in adult rat cardiac fibroblasts in response to interleukin-1β. J Biol 
Chem 279: 39513–39519, 2004. 
54.  Yang DQ, Kastan MB. Participation of ATM in insulin signalling through 
phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol 2: 893–898, 2000. 
55.  Zhan H, Aizawa K, Sun J, Tomida S, Otsu K, Conway SJ, McKinnon PJ, Manabe I, 
Komuro I, Miyagawa K, Nagai R, Suzuki T. Ataxia telangiectasia mutated in cardiac 
fibroblasts regulates doxorubicin-induced cardiotoxicity. Cardiovasc Res 110: 85–95, 
2016. 
56.  Zhang X, Yang H, Yue S, He G, Qu S, Zhang Z, Ma B, Ding R, Peng W, Zhang H, Yang 
Z, Dou K, Tao K, Li X. The mTOR inhibition in concurrence with ERK1/2 activation is 
involved in excessive autophagy induced by glycyrrhizin in hepatocellular carcinoma. 
Cancer Med 6: 1941–1951, 2017. 
57.  Zhu B, Zhou Y, Xu F, Shuai J, Li X, Fang W. Porcine circovirus type 2 induces 
autophagy via the AMPK/ERK/TSC2/mTOR signaling pathway in PK-15 Cells. J Virol 
86: 12003–12012, 2012. 
54 
 
 CHAPTER 3 
ATAXIA-TELANGIECTASIA MUTATED KINASE DEFICIENCY AUGMENTS 
AUTOPHAGIC RESPONSE IN THE INFARCT REGION IN A CHRONIC MYOCARDIAL 
INFARCTION MODEL 
 
Patsy R. Thrasher1; Laura L. Daniel1; Suman Dalal1; Mahipal Singh1; Krishna Singh1,2,3 
 
1Department of Biomedical Sciences, James H Quillen College of Medicine 
2Center for Inflammation, Infectious Disease and Immunity 
3James H Quillen Veterans Affairs Medical Center 
East Tennessee State University 
Johnson City, TN, USA 
 
Running title: ATM and Autophagy late post-MI  
 
Total number of figures: 5         
 
Key words: ATM, autophagy, heart, myocardial infarction  
 
 
*Correspondence: Krishna Singh, Ph.D.  
Department of Biomedical Sciences 
James H Quillen College of Medicine  
East Tennessee State University  
PO Box 70582, Johnson City, TN 37614  
Ph: 423-439-2049  
Fax: 423-439-2052  
E-mail: singhk@etsu.edu 
 
 
 
 
 
 
55 
 
Abstract 
Ataxia-telangiectasia mutated kinase (ATM) is a cell cycle checkpoint protein activated in 
response to oxidative stress and DNA damage. We have previously shown that ATM deficiency 
impairs autophagic response in the heart early during myocardial infarction (MI). Here, we tested 
the hypothesis that ATM deficiency augments autophagy in the heart in a chronic MI (28 days 
post-MI) setting. MI was induced in wild-type (WT) and ATM heterozygous knockout (hKO) 
mice by ligating the left anterior descending artery (LAD). Levels of LC3-II and p62, major 
markers of autophagy, remained unchanged in the non-infarct region of the heart. Interestingly, 
MI altered autophagy in the infarct region of both WT and hKO hearts as evidenced by increased 
LC3-II and Beclin protein levels coupled with decreased p62 protein levels. However, Levels of 
LC3-II and cathepsin D were significantly higher in hKO-infarct hearts versus WT-infarct. 
Activation of AMPK was higher in the WT-Infarct group, while activation of Akt and mTOR 
was higher in the hKO-infarct versus WT-Infarct group.  In vitro, treatment of cardiac fibroblasts 
using KU-55933, an inhibitor of ATM, augmented autophagy as evidenced by increased LC3-II 
protein levels and decreased p62 protein levels. Thus, ATM deficiency results in autophagic 
augmentation in the infarct region of the heart 28 days post-MI and in cardiac fibroblasts.  
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Introduction 
Heart failure is the number one cause of death worldwide (12). Myocardial infarction 
(MI) is the most common cause of heart failure (31). Following MI, the heart undergoes 
remodeling, a process that ultimately changes the architecture and composition of the left 
ventricle(33). Macroautophagy, hereafter referred to as autophagy, is a degradative process in the 
body that serves to maintain cellular homeostasis by packaging cytoplasmic components into 
autophagosomes for eventual degradation by lysosomes (6, 16, 20, 26). Autophagy maintains 
homeostasis under normal conditions and is suggested to play a critical role in the development 
of pathologies such as cancer, diabetes, and heart failure (6, 15, 26). It is shown to play a key 
role in myocyte apoptosis and cardiac remodeling post-MI (16, 43). Autophagy is activated in 
cardiac myocytes within 30 minutes following permanent coronary ligation in a mouse model 
(16). Autophagic activity was particularly higher in myocytes bordering the infarcted region 
(16). Furthermore, pharmacological inhibition of autophagy increased infarct size by 31% (16), 
while pharmacological activation of autophagy attenuated cardiac remodeling and dysfunction 7 
and 21 days post-MI (43). Thus, autophagy is considered cardioprotective and could serve as a 
therapeutic strategy for both acute and chronic MI.  
Ataxia-telangiectasia mutated kinase (ATM) is a serine/threonine kinase typically 
activated in response to DNA damage (1, 25). Although it is primarily located in the nucleus, it is 
suggested to have cytoplasmic functions including regulating responses to an array of genotoxic 
stresses in addition to mediating several metabolic pathways (4, 13, 39, 46). Individuals with a 
mutation in the ATM gene develop a multisystemic disease known as Ataxia Telangiectasia (AT) 
(14, 29, 46). These individuals make up roughly 1.4 to 2% of the population (17, 22) and are at a 
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higher risk of death between ages 20 and 79 (34). Previously, we examined the role of ATM in 
autophagy early (4 hours) during MI (38). It was observed that ATM deficiency impairs 
autophagic response under basal conditions as well as following MI (38). This impairment in 
autophagy during ATM deficiency associated with activation of GSK-3β and mTOR, and 
inactivation of Akt and AMPK (38). In the present study, we tested the hypothesis that ATM 
deficiency augments autophagic response in the heart late post-MI (28 days after its onset). The 
data presented here suggests that ATM deficiency augments autophagy in the infarcted region of 
the heart 28 days post-MI, which associates with the activation of Akt and mTOR.  
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Materials and Methods 
Vertebrate Animals 
This study conforms to the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). All 
experiments were performed in accordance with the protocols approved by the East Tennessee 
State University Committee on Animal Care. ATM deficient mice (129xblack Swiss hybrid 
background), generated as described (3), were purchased from Jackson Laboratory. Age-matched 
(aged ~4 months) female and male mice were used for the study. Since homozygous knockout 
mice die at roughly 2 months of age from thymic lymphomas (3), the study used ATM 
heterozygous knockout (hKO; deficient) mice. All mice undergoing surgery (Sham and MI) 
received buprenorphine injections prior to and 24 hours following surgery.  
Myocardial Infarction 
Myocardial infarction (MI) was performed as previously described (9). Briefly, mice 
were anesthetized with a mixture of isoflurane (2%) and oxygen (0.5 l/min) inhalation and 
ventilated using a rodent ventilator (Harvard Apparatus). Body temperature was maintained at 
∼37°C using a heating pad. The heart was exposed by a left thoracotomy. The left anterior 
descending coronary artery (LAD) was ligated using a 7-0 polypropylene suture. Sham-operated 
mice underwent the same procedure without ligation of the LAD. At the end of the study period 
(28 days following LAD ligation), isolated hearts were separated into infarct and non-infarcted 
LV regions for molecular analyses.   
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Fibroblast isolation and treatment  
Adult rat cardiac fibroblasts were isolated as previously described (45). The cells were 
grown to confluence in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
heat-inactivated fetal bovine serum. The cells were serum starved for 5 hours prior to use. The 
cells were then treated with the ATM inhibitor KU-55933 (KU; 100 μM; Tocris) for 24 hours. 
The cells were maintained in serum-free DMEM for the duration of the treatment.  
Western blot analysis 
LV or cell lysates were prepared in RIPA buffer [10 mM Tris·HCl (pH 7.2), 158 mM 
NaCl, 1 mM EGTA, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 1 mM sodium 
orthovanadate, and 0.2 mM phenylmethylsulfonyl fluoride] supplemented with protease 
inhibitors. Equal amounts of proteins (25 μg) were resolved using SDS-PAGE. The proteins 
were then transferred to a PVDF membrane. The membrane was blocked for one hour using 5% 
nonfat milk and incubated overnight with primary antibodies against LC3B (1:1000), p62 
(1:1000), p-Akt (ser-473; 1:1000), p-GSK-3β (ser-9; 1:1000), p-mTOR (ser-2448; 1:1000), p-
Erk1/2 (1:1000) (Cell Signaling), cathepsin D (1:1000), Beclin (1:000), or p-AMPK (thr-172; 
1:1000) (Santa Cruz). The immune-complexes were detected using appropriate secondary 
antibodies and chemiluminescent reagents. There were no significant differences in GAPDH 
levels between genotypes or groups, therefore GAPDH (1:10,000; Cell Signaling) 
immunostaining was used as the protein loading control. Protein signals were visualized using 
ImageQuant LAS 500 imager and quantified using ImageQuant TL software (GE).  
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Statistical analysis 
Data are expressed as means ± SE. Data were analyzed using Student's t-test or a two-
way analysis of variance followed by the Student-Newman-Keuls test. P values of <0.05 were 
considered to be significant. 
Results 
Expression of autophagy-related proteins in cardiac tissue 
LC3 is considered to be one of the most important markers of autophagy as it is essential 
to autophagosome formation (28). In mammalian cells, LC3 is processed to LC3-I and 
subsequently LC3-II by the addition of phosphatidylethanolamine (PE) (28). p62, an autophagy 
receptor, aids in the tagging and transportation of misfolded proteins to the autophagosome by 
working in conjunction with the ubiquitin-proteasome pathway (23). Western blot analysis 
showed increased levels of LC3-II in hKO-sham versus WT sham (Fig 3.1A). However, LC3-II 
protein levels remained unchanged in the non-infarct LV in both genotypes when compared to 
the respective sham groups. No significant differences were observed in p62 protein levels 
among the four groups (Fig 3.1B). In the infarct LV region, there was a significant increase in 
LC3-II protein levels in both MI groups. Interestingly, the levels of LC3-II protein were 
significantly greater in hKO-MI group versus WT-MI (*p˂0.05 vs respective sham; #p˂0.05 vs 
WT-Inf; n=4-5; Fig 3.2A). The levels p62 were decreased to a similar extent in the two MI 
groups when compared to their respective shams (*p˂0.05 vs respective sham; n=4-5; Fig 3.2B). 
Based on these observations, infarct LV lysates were used for further molecular analysis.    
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Beclin, a mammalian ortholog of the yeast autophagy-related gene 6 (Atg6), also plays a 
critical role in autophagosome formation (42). Beclin acts during the initiation stage of 
Figure 3.1. LC3-II and p62 protein levels 28 days post-MI in the non-infarct region. Total LV 
lysates, prepared from sham and infarct (Non) regions post-MI, were analyzed by western blot 
using anti-LC3B (A) and anti-p62 (B) antibodies. Top: western blots exhibiting 
immunostaining for LC3-I, LC3-II, p62, and GAPDH. Bottom: quantitative analyses of LC3-
II and p62 protein levels normalized to GAPDH (*p˂0.05 vs respective sham; n=3-4). 
Figure 3.2. LC3-II and p62 protein levels 28 days post-MI in the infarct region. Total LV 
lysates, prepared from sham and infarct (Inf) regions post-MI, were analyzed by western blot 
using anti-LC3B (A) and anti-p62 (B) antibodies. Top: western blots exhibiting 
immunostaining for LC3-I, LC3-II, p62, and GAPDH. Bottom: quantitative analyses of LC3-
II and p62 protein levels normalized to GAPDH (*p˂0.05 vs respective sham; #p˂0.05 vs 
WT-Inf; n=4-5). 
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autophagy by forming the isolation membrane, a double-membrane structure that engulfs 
cytoplasmic material to form the autophagosome (42). Although there was no significant 
difference in Beclin protein levels in hKO-sham versus WT-sham group, Beclin protein levels 
were increased to a similar extent in the infarct region of both WT and hKO groups (*p˂0.05 vs 
respective sham; n=3-4; Fig 3.3A).   Cathepsin D is a lysosomal endopeptidase involved in 
lysosomal degradation of misfolded proteins (37). p62 and cathepsin D play a critical role in 
autophagic clearance or autophagolysosome degradation. Cathepsin D protein levels were also 
not significantly different between the two sham groups (Fig 3.3B). Cathepsin D protein levels 
remained unchanged in the infarct region of WT-MI group, however, there was a significant 
increase in cathepsin D protein levels in hKO-MI group versus WT-MI group (#p˂0.05 vs WT-
Inf; n=3-4; Fig 3.3B). 
 
 
 
 
Figure 3.3. Beclin and cathepsin D protein levels 28 days post-MI in the infarct region. Total 
LV lysates, prepared from sham and infarct (Inf) regions post-MI, were analyzed by western 
blot using anti-Beclin (A) and anti-cathepsin D (B) antibodies. Top: western blots exhibiting 
immunostaining for Beclin, cathepsin D, and GAPDH. Bottom: quantitative analyses of 
Beclin and cathepsin D protein levels normalized to GAPDH (*p˂0.05 vs respective sham; 
#p˂0.05 vs WT-Inf; n=3-4). 
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Activation of signaling molecules related to autophagy 
Typically, Akt, AMPK, and Erk1/2 signaling are all positive regulators of autophagy (7, 
24, 35, 41), while mTOR is a well-known negative regulator of autophagy (18, 19). 
Phosphorylation of Akt, AMPK, Erk1/2, and mTOR was not significantly different between the 
two sham groups (*p˂0.05 vs respective sham; #p˂0.05 vs WT-Inf; n=3-4; Fig 3.4A-D). 
However, phosphorylation of Akt was greater in the infarct region of hKO-MI, not in WT-MI, 
group versus hKO-sham (Fig 3.4A). On the other hand, AMPK phosphorylation was 
significantly greater in in the infarct region of WT-MI, not in hKO-MI, group versus WT-sham 
and hKO-MI (Fig 3.4B). MI led to a similar increase in Erk1/2 phosphorylation in the infarct 
region of both genotypes (Fig 3.4C). Increased phosphorylation of mTOR was only observed in 
the infarct region of hKO-MI group which was found to be significantly greater versus the WT-
MI group (Fig 3.4D).   
64 
 
 
 
 
Autophagic response in cardiac fibroblasts  
Cardiac fibroblasts play an important role in fibrosis deposition in the heart post-MI (36). 
Fibroblasts participate in the healing process of the heart by differentiating into myofibroblasts 
(5). Myofibroblasts are found in the infarct region of the heart following MI and aid in wound 
closure (8). Previously, we found that inhibition of ATM with KU (100 µM) for 4 hours 
negatively regulated autophagy in cardiac fibroblasts (38). Here, we investigated if autophagy is 
positively or negatively regulated in cardiac fibroblasts 24 hours following treatment with ATM 
Figure 3.4. Activation of Akt, AMPK, Erk1/2, and mTOR 28 days post-MI in the infarct 
region. Total LV lysates, prepared from sham and infarct (Inf) regions post-MI, were analyzed 
by western blot using anti-p-Akt (A), anti-p-AMPK (B), anti-p-Erk1/2 (C), and anti-p-mTOR 
(D) antibodies. Top: western blots exhibiting immunostaining for p-Akt, p-AMPK, p-Erk1/2, 
p-mTOR, and GAPDH. Bottom: quantitative analyses of p-Akt, p-AMPK, p-Erk1/2, and p-
mTOR normalized to GAPDH (*p˂0.05 vs respective sham; #p˂0.05 vs WT-Inf; n=3-4). 
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inhibitor, KU-55933 (KU). Western blot analyses of cell lysates showed a significant increase in 
LC3-II (*p˂0.05 vs CTL; n=4; Figure 3.5A) protein levels coupled with a significant decrease in 
p62 protein levels (*p˂0.05 vs CTL; n=4; Figure 3.5B) in KU-treated cells.  
 
 
 
 
Discussion 
We have previously shown that ATM deficiency results in autophagic impairment early 
during MI (38). This is the first study investigating the role of ATM in cardiac autophagy in a 
chronic setting post-MI in mice. A major finding of this study is that ATM deficiency does not 
impair autophagic response in the non-infarct LV region 28 days post-MI. However, it augments 
autophagy in the infarct region via a different mechanism(s) than WT hearts. MI augments 
autophagy in the infarct regions of both WT and hKO hearts as evidenced by increased LC3-II 
and Beclin protein levels and decreased p62 protein levels. However, changes in autophagy may 
be more pronounced during ATM deficiency as evidenced by increased protein levels of LC3-II 
Figure 3.5. LC3-II and p62 protein levels in cardiac fibroblasts. Serum-starved cardiac 
fibroblasts were treated with KU-55933 (100 µm; ATM inhibitor) for 24 hours. Total cell 
lysates were analyzed by western blot using LC3B (A) and p62 (B) antibodies. Top: western 
blot exhibiting immunostaining for LC3-I, LC3-II, p62, and GAPDH. Bottom: quantitative 
analysis of LC3-II normalized to GAPDH (*p˂0.05 vs CTL; n=4). 
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and cathepsin D. Furthermore, autophagic changes in WT hearts post-MI associates with 
enhanced AMPK activation, while autophagic changes in hKO hearts post-MI associates with 
enhanced Akt and mTOR activation. ERK1/2 activation was increased to a similar extent in both 
MI groups. In vitro, ATM inhibition for 24 hours resulted in altered autophagic response in 
cardiac fibroblasts as evidenced by an increase in LC3-II protein levels coupled with a decrease 
in p62 protein levels.  
Concurring with our previous finding that ATM alters autophagy at basal levels (38), 
LC3-II protein levels were significantly higher in ATM deficient hearts under basal conditions. 
However, there were no significant changes in Beclin, p62, or cathepsin D protein levels or 
signaling molecules related to autophagy in ATM deficient hearts. In our previous study, p62 
protein levels were higher, while mTOR phosphorylation was lower in ATM deficient hearts 
under basal conditions (38). The reasons for these discrepant findings may include the age of the 
animals. In our previous study, the animals were ~4 months of age, while the mice in the current 
study are ~5 months of age. Autophagy is a dynamic process (27). It is possible that autophagic 
flux may change with age. However, further investigations are needed to explore this possibility. 
Although autophagy is typically upregulated post-MI, studies have shown that autophagic 
activity often fluctuates throughout the duration of MI (16, 43). While it has been shown that 
autophagy is sharply induced 12-24 hours post-MI in the infarct boarder zone, it has also been 
shown to decrease 5-21 days post-MI in that same region (43). However, autophagosomes have 
been detected in surviving cardiomyocytes in chronic stages of MI, connecting autophagy to 
cardiac myocyte survival during the later stages of MI (21). We have previously shown that MI 
results in autophagic induction 4 hours during MI in WT hearts as evidenced by high LC3-II 
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protein levels coupled with reduced aggregate accumulation (38). Furthermore, phosphorylation 
of Erk1/2 was also higher 4 hours during MI in WT hearts (38). In the present study, MI resulted 
in autophagic augmentation 28 days post-MI in the infarct region as evidenced by an increase in 
both LC3-II and Beclin protein levels coupled with a decrease in p62 protein levels. 
Interestingly, phosphorylation of Erk1/2 and AMPK were significantly higher in the infarct 
region of WT hearts post-MI. Both AMPK and Erk1/2 have been implicated in the regulation of 
autophagy, typically acting as positive regulators of autophagic activity. Intermedin, a 
proopiomelanocortin-derived peptide, attenuated MI injury through the activation of autophagy 
in a rat model of ischemic heart failure via the activation of MAPK/ERK1/2 pathways (40). The 
compound curcumin induced autophagy in malignant glioma cells by activating Erk1/2 (32). 
Furthermore, inhibition of the Erk1/2 pathway inhibited curcumin-induced autophagy and 
apoptosis (32). AMPK, the energy sensor in cells, is a key player in the heart’s response to stress 
(e.g. ischemia) (30). Under glucose starvation, AMPK promotes autophagy by directly activating 
Ulk1 via the phosphorylation of Ser 317 and Ser 777 (2, 18). Genetic inhibition of AMPK in 
cardiac myocytes attenuates cardiac autophagy, exacerbates cardiac dysfunction, and increases 
mortality in diabetic mice (44). Although Erk1/2 and AMPK signaling pathways have 
independently been shown to activate autophagy, there is evidence to suggest that an interplay 
between the two pathways may play an important role in the regulation of autophagy. Porcine 
circovirus type 2 induces autophagy in PK-15 cell via AMPK/Erk1/2 signaling (47). Thus, it is 
possible that the augmentation of autophagy in the infarct region 28 days post-MI in WT hearts 
may be due to Erk1/2 and AMPK signaling acting independently or in conjunction.  
Similar to WT hearts post-MI, there was a significant increase in LC3-II and Beclin 
protein levels 28 days post-MI in the infarct region of ATM deficient hearts coupled with a 
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decrease in p62 protein levels. Together, these results suggest that MI alters autophagy in the 
infarct region of ATM deficient hearts 28 days post-MI as well. However, the mechanism(s) by 
which autophagy is augmented in ATM deficient hearts appear to be different than that of WT 
hearts. Although Erk1/2 activation was increased to a similar extent in both genotypes post-MI, 
activation of Akt and mTOR was higher in ATM deficient hearts post-MI. Activation of Akt and 
Erk1/2 is shown to positively regulate autophagy (35), while activation of mTOR is known to 
negatively regulate autophagy (7). Thus, it is possible that the autophagic changes in ATM 
deficient hearts post-MI involves both Akt and Erk1/2 signaling that is independent of mTOR 
activation.  
Previously we have provided evidence that cardiac cell apoptosis is lower in the infarct 
region of ATM deficient hearts when compared to their WT counterparts 28 days post-MI (10). 
This decrease in apoptosis associated with decreased activity of GSK-3β, a pro-apoptotic kinase 
(10). Activation of Akt is known to phosphorylate and inactivate GSK-3β (11). Consistent with 
these observations, we observed enhanced activation of Akt in ATM deficient hearts.  ATM 
deficient hearts also exhibited higher levels of LC3-II and cathepsin D protein in the infarct 
region indicating augmented autophagy during ATM deficiency post-MI.  Inhibition of GSK-3β 
using CHIR99021 induced an autophagic response in human pancreatic cancer cells (24) and 
knockdown of GSK-3β increased basal autophagy in human aortic endothelial cells (41). Thus, it 
is possible that the alterations in autophagy in the infarct region of ATM deficient is due to 
inactivation of GSK-3β (phosphorylation) despite a decrease in AMPK activity and increase in 
mTOR activity. Together, these data provide evidence for a link between Akt/GSK-3β pathway, 
apoptosis, and autophagy in the infarct region of ATM deficient hearts 28 days post-MI. It is 
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possible that cardiac cell apoptosis is lower in ATM deficient hearts since autophagy is altered in 
response to activation of Akt and inactivation of GSK-3β. 
Fibroblasts play a central role in post-MI repair and remodeling. In fact, fibroblasts 
constitute the majority of cells in the infarcted area during the infarct healing phase post-MI (36). 
Treatment of adult cardiac fibroblasts with the ATM inhibitor KU-55933 for 24 hours resulted in 
autophagic changes as evidenced by an increase in LC3-II protein levels and a decrease in p62 
protein levels. In our previous study, we provided evidence that treatment of cardiac fibroblasts 
with ATM inhibitor KU-55933 for 4 hours results in autophagic impairment in adult cardiac 
fibroblasts as levels of LC3-II protein were lower in KU-treated cells (38). Together, these 
results provide evidence that autophagic activity changes over time in cardiac fibroblasts in 
response to ATM inhibition, an observation similar to ATM deficient hearts post-MI. The 
autophagic changes seen 4 hours post ATM inhibition (38) are different from those seen 24 
hours post ATM inhibition.  
In summary, both WT and hKO hearts exhibited augmented autophagy in the infarct 
regions, not the non-infarct region, 28 days post-MI. Autophagic changes are more pronounced 
in ATM deficient hearts post-MI as well as in cardiac fibroblasts treated with ATM inhibitor. 
The signaling molecules involved in autophagic changes appeared different between the two 
genotypes. Autophagy changes in WT hearts post-MI may involve the activation of AMPK and 
Erk1/2, while autophagy changes in hKO hearts post-MI involves activation of Akt and Erk1/2 
that appears to be mTOR independent. Autophagy regulation in ATM deficient hearts may also 
occur via the involvement of Akt-mediated inactivation of GSK-3β. It should be emphasized that 
our collective data investigating the role of ATM in cardiac autophagy are obtained 4 hours post-
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MI (38) or 28 days post-MI. Intermediate time points between 4 hours and 28 days post-MI may 
be helpful to understand the full scope of molecular changes involved in autophagic flux during 
ATM deficiency post-MI.     
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Abstract 
Abnormalities in glucose metabolism are implicated in the progression of heart failure. Ataxia-
telangiectasia mutated kinase (ATM) is a cell cycle checkpoint protein activated in response to 
DNA damage. Mutations in ATM cause a multisystemic disease known as Ataxia-telangiectasia 
(AT) that is often accompanied by glucose intolerance. Previous work from our lab has shown 
that lack of ATM induces structural and functional changes in the heart. Here we tested the 
hypothesis that lack of ATM alters cardiac glucose and TCA cycle metabolism with or without 
ischemia. Isolated wild-type (WT) and ATM knockout (KO) hearts underwent retrograde 
perfusion through the aorta using KH buffer containing U-13C6 glucose for 30 minutes. A 
separate group of hearts also underwent global ischemia for 20 minutes. Analyses of metabolome 
reservoir for the incorporation of 13C using nuclear magnetic resonance (NMR) spectroscopy and 
ion chromatography mass spectrometry (IC-MS) revealed that lack of ATM accelerates 
glycolysis and gluconeogenesis in non-ischemic hearts in addition to augmenting TCA cycle 
metabolism. Global ischemia augments the gluconeogenic pathway in WT hearts, while it 
augments the glycolytic pathway in KO hearts that is associated with TCA cycle changes. 
Additionally, global ischemia has no effect on glycolytic or gluconeogenic pathways with 
minimal effects on TCA cycle metabolism in KO hearts compared to WT hearts. 
Phosphorylation of AMPK decreased post-ischemia in both WT and KO hearts, while it 
increased in KO hearts under non-ischemic and ischemic conditions compared to WT hearts. 
Glut4 protein expression decreased in KO hearts when compared to KO non-ischemic and WT 
ischemic hearts. Activation of Akt was lower, while activation of GSK-3β was higher post-
ischemia in WT and KO hearts. Non-ischemic KO hearts also exhibited lower Akt activation and 
higher GSK-3β activation when compared to WT non-ischemic hearts. Thus, ATM affects 
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cardiac metabolites with and without ischemia which associated with changes in activation of 
Akt, GSK-3β, and AMPK alongside alterations in Glut4 protein levels. 
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Introduction 
Heart failure is the leading cause of death and disability globally (28, 35) and is estimated 
to increase 25% by 2030 (35). Heart failure is a complex syndrome that results from a plethora of 
diseases, ranging from diabetes, hypertension, and ischemic heart disease (35). However, a 
common thread that runs through the various etiologies leading to heart failure is modified 
cardiac metabolism (35). Recent studies reveal that metabolic remodeling is a prominent feature 
of heart failure (28, 35). Thus, metabolic therapy has risen as a promising approach to treating 
heart disease (32).  
Under normal conditions or normoxia, glycolysis and the tricarboxylic acid (TCA) cycle 
contribute roughly 5% of the total ATP produced (11, 27, 28). Ischemia is associated with 
dramatic metabolic abnormalities in the heart, causing changes to organ function and even 
eventual heart failure (1, 27). One of the modifications that occurs in cells under ischemic 
conditions is the switch from aerobic to anaerobic metabolism (1), resulting in the predominant 
use of carbohydrates like glucose as an energy substrate (1, 27). Glucose uptake and glycolysis 
are accelerated in an effort to maintain myocardial energetics during myocardial ischemia (10, 
27, 28, 32). In fact, increased glucose metabolism has been implicated in the progression of heart 
failure as it is upregulated in hypertrophied hearts (22). Dysfunction or depletion of the TCA 
cycle results in a decline in cardiac function (19). In addition to glycolysis, gluconeogenesis, 
another carbohydrate metabolism pathway, is also critical in the maintenance of cell energy 
homeostasis under normal and ischemic conditions (1). Although predominantly shown in liver, 
gluconeogenesis has been shown to increase in the rabbit heart under non-ischemic and ischemic 
conditions (1).  
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Ataxia-telangiectasia mutated kinase (ATM), a serine/threonine kinase, is generally 
activated in response to oxidative stress and DNA damage. It plays a critical role in cell cycle 
arrest and DNA repair. Although primarily located in the nucleus, it is found in the cytoplasm 
where it is suggested to play a pivotal role in metabolic pathways (7). It is suggested to modulate 
carbon metabolism in cancer cells (7, 24, 31). Deficiency of ATM affects metabolic parameters 
in mice (31). ATM+/- mice fed a western diet were glucose intolerant and insulin resistant 
compared to ATM+/+ mice (31). Furthermore, ATM+/- mice had higher systolic and diastolic 
blood pressure (31). Mutations in the ATM gene cause an immunodeficiency and neuronal 
degeneration disease called Ataxia-telangiectasia (AT), a disorder that affects 1:40,000-
1:100,000 people worldwide (7). AT patients exhibit many characteristics of metabolic disease, 
including susceptibility to diabetes and impaired glucose metabolism (33).   
Previous work from our lab has shown that lack of ATM induces structural and 
functional parameters of the heart (18). We have also provided evidence that ATM plays an 
important role in myocyte apoptosis and myocardial remodeling following myocardial infarction 
and β-adrenergic receptor stimulation (8, 9, 16, 17). Here, we tested the hypothesis that lack of 
ATM alters cardiac glucose and TCA cycle metabolism pre- and post-myocardial ischemia. The 
data presented here suggest that lack of ATM alters glucose and TCA cycle metabolism in the 
heart before and after global ischemia that associates with changes in the activation of AMPK, 
Akt, GSK-3β and Glut4 protein levels.  
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Materials and Methods 
Vertebrate Animals  
This investigation conforms to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). All 
the experiments were performed in accordance with the protocols approved by the East 
Tennessee State University Committee on Animal Care. ATM heterozygous mice (129xblack 
Swiss hybrid background), generated as described(3), were purchased from Jackson Laboratory. 
ATM homozygous knockout (KO) mice were generated by breeding ATM heterozygous mice. 
Genotyping was performed by PCR using primers suggested by the Jackson Laboratory. Age-
matched (~ 2-month-old) male and female (WT and KO) mice were used for the study.  
Langendorff perfusion of heart with 13C6-glucose  
Hearts were excised from WT and KO mice and briefly washed in PBS to remove excess 
blood. Hearts were then immediately perfused retrogradely with KH buffer containing U-13C6 
glucose [(in mmol/L) 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 24.8 NaCHO3, 2.5 CaCl2, 
and 10.6 U-13C6 glucose] for 30 minutes as previously described (38). The KH buffer was 
maintained at 37°C and equilibrated with 95% oxygen and 5% carbon dioxide. Flow rate was 
measured using the Transonic Systems Inc. T106 Small Animal Flow Meter. There was no 
significant difference in flow rate between WT and KO hearts (data not shown).  
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Quenching and extraction of polar compounds, lipids, and proteins  
At the end of the 30 minute period, a group of hearts were subjected to 20 minutes of 
global ischemia. Tissue extraction was performed as previously described (13). Briefly, hearts 
were snap frozen and ground into powder using liquid nitrogen. Roughly 20 mg of tissue powder 
was placed into a 15 mL polypropylene conical centrifuge tube and shaken vigorously in a 
mixture of chilled acetonitrile (2 mL), nanopore water (1.5 mL), and HPLC-grade chloroform (1 
mL). The mixture was centrifuged at 3500xg for 20 minutes at room temperature to separate the 
polar (top), tissue debris (primarily denatured proteins; middle), and lipid (bottom) layers. The 
polar and lipid layers were collected, and the tissue debris layer was further extracted using 0.5 
mL of chloroform: methanol: butylated hydroxytoluene (BHT) (2:1:1 ratio). The tissue debris 
layer, collected in a 1.5 microfuge tube, was centrifuged at 14,000xg for 20 minutes at 4°C to 
separate the three phases again. The extracted polar and lipid fractions were pooled with their 
main fractions. The polar and tissue debris fractions were lyophilized overnight, and the dry 
weight of tissue debris was used to normalize the metabolic content. The polar extracts were 
redissolved in 100% D2O comprised of 30 nmol perdeuterated 2,2′-dimethyl-2-silapentane-5-
sulfonate (DSS) as an internal chemical shift and concentration reference for Nuclear Magnetic 
Resonance (NMR) measurement.        
Determination of cardiac metabolites incorporated with 13C 
Lyophilized samples from both WT and KO hearts were analyzed using Ion 
Chromatography Mass Spectrometry (IC-MS) and Nuclear Magnetic Resonance (NMR) 
spectroscopy to determine cardiac metabolites as previously described (13).   
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Preparation of myocardial tissue for western blot analysis  
WT and KO hearts were perfused retrogradely with Krebs-Henseleit (KH) buffer [(in 
mmol/L) NaCl 118, NaHCO3 25, KCl 4.75, MgSO4 1.2, KH2PO4 1.2, CaCl2 1.9 and glucose 
11.9] for 30 minutes. A group of the hearts as also subjected to 20 minutes of global ischemia. 
The hearts were then snap frozen in liquid nitrogen, pulverized, and suspended in RIPA buffer 
[10 mM Tris-HCl (pH 7.2), 158 mM NaCl, 1 mM EGTA, 0.1% SDS, 1% sodium deoxycholate, 
1% Triton X-100, 1 mM sodium orthovanadate, 0.2 mM phenylmethylsulfonyl fluoride] with 
added protease inhibitors for protein analysis.   
Western blot analysis  
Equal amounts of heart lysates (25 μg) were resolved using SDS-PAGE. The proteins 
were then transferred to a PVDF membrane. The membrane was blocked for one hour using 5% 
nonfat milk and incubated overnight with primary antibodies against p-Akt (ser-473; 1:1000), p-
GSK-3β (ser-9; 1:1000), Akt (1:1000), GSK-3β (1:1000), AMPK (1:1000) (Cell Signaling), p-
AMPKα (1:1000), or Glut4 (1:1000) (Santa Cruz). Total protein immunostaining was used as a 
loading control for phosphorylated proteins, while GAPDH was used as a loading control for 
Glut4 protein. The immune-complexes were detected using appropriate secondary antibodies and 
chemiluminescent reagents. Protein signals were visualized using ImageQuant LAS 500 imager 
and quantified using ImageQuant TL software (GE). 
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Statistical analysis 
Data are expressed as means ± SE. Data were analyzed using a two-way analysis of 
variance followed by the Student-Newman-Keuls test. P values of <0.05 were considered to be 
significant. 
Results 
Glycolytic metabolites  
Formation of glucose-6-phosphate (G6P) is the first reaction of glycolysis. G6P can then 
be converted into pyruvate through a multi-step process involving the formation of fructose-6-
phosphate (F6P) and phosphoenolpyruvate (PEP). Alternatively, it can be converted into 
glucose-1-phosphate (G1P) for conversion into glycogen. Using 13C6-glucose (+6) isotopomer 
perfusion in isolated hearts, we observed significantly higher levels of six labelled carbon 
metabolites (+6 G1P, G6P and F6P; Fig 4.1A-C) and three labelled carbon metabolites (Fig 4.1D 
and 4.1F) in ATM deficient hearts versus WT (Fig 4.1A-C). The levels of labelled metabolites 
was ~4.8, 9.7, 7.0, 4.6 and 2.7 fold higher for G6P, F6P, G1P, PEP and pyruvate, respectively, in 
ATM deficient hearts vs WT without ischemia. Global ischemia (20 minutes) did not change 
levels of G6P, F6P and G1P in WT group. However, the levels of  three carbon labelled 
metabolites, PEP and pyruvate, were significantly lower in WT-ischemic group vs WT-non-
ischemic group. On the other hand, global ischemia in ATM KO hearts led to a significant 
decrease in all five metabolites vs KO-non-ischemic group (Fig 4.1A-1E). In fact, there was no 
significant difference in the levels of six or three carbon metabolites between the two ischemic 
groups. 
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Gluconeogenic metabolites  
Using 13C6-glucose (+6) isotopomer perfusion in isolated hearts, we observed 
significantly higher levels of three carbon labelled (+3) metabolites, G1P and F6P, in ATM 
deficient hearts versus WT (Fig 4.2A, 4.2C). Global ischemia (20 minutes) increased the levels 
of three carbon labelled metabolites G1P, G6P, and F6P in WT group. However, global ischemia 
did not change levels of three carbon labelled metabolites (G1P, G6P, and F6P) in KO-ischemic 
Figure 4.1. Glycolytic metabolites. Levels of glycolytic metabolites were measured in WT and 
KO hearts 20 minutes post-ischemia using Ion Chromatography Mass Spectrometry (IC-MS). 
A: G1P (+6). B: G6P (+6). C: F6P (+6). D: PEP (+3). E: Pyruvate (+3). *p<0.05 vs. WT-non; 
#
p<0.05 vs. KO-non; n=3-7. G1P, Glucose-1-Phosphate; G6P, Glucose-6-Phosphate; F6P, 
Fructose-6-Phosphate; PEP, Phosphoenolpyruvate. (+n) represents the number of 
13
C carbons 
incorporated into that metabolite.   
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group vs KO-non-ischemic group (Fig 4.2A-4.2C). There was no significant difference in the 
levels of three carbon labelled metabolites between the two ischemic groups.   
 
 
 
Glycogen and Lactate levels 
There was no difference in glycogen levels between WT and KO hearts under non-
ischemic Glycogen levels were significantly decreased post-ischemia in both groups with no 
difference between the two genotypes (WT-non, 9.27±1.69 nmol/mg; WT-isch, 1.16±0.41* 
nmol/mg; KO-non, 8.81±1.84 nmol/mg; KO-isch, 0.50±0.34# nmol/mg; *p<0.05 vs. WT-non; 
#p<0.05 vs. KO-non; n=3-5; Figure 4.3A). There were no significant changes in lactate (+3) 
levels in the heart (WT-non, 1059864.79±653274.58 nmol/g/protein; WT-isch, 
Figure 4.2. Gluconeogenic metabolites. Levels of gluconeogenic metabolites were measured 
in WT and KO hearts 20 minutes post-ischemia using IC-MS. A: G1P (+3). B: G6P (+3). C: 
F6P (+3). *p<0.05 vs. WT-non; n=3-7. G1P, Glucose-1-Phosphate; G6P, Glucose-6-
Phosphate; F6P, Fructose-6-Phosphate. (+n) represents the number of 
13
C carbons 
incorporated into that metabolite.   
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2393917.12±1125072.61 nmol/g/protein; KO-non, 2630613.33±1606850.02 nmol/g/protein; 
KO-isch, 5801752.79±2585945.95 nmol/g/protein; n=5-7; Figure 4.3B).  
 
 
 
TCA cycle metabolites  
Citrate levels  
Citrate levels were not different between the two non-ischemic groups. Global ischemia 
decreased citrate levels to a similar extent in both groups (WT-non, 320.12±134.82 
nmol/g/protein; WT-isch, 40.42±9.18* nmol/g/protein; KO-non, 236.70±49.32 nmol/g/protein; 
KO-isch, 104.37±40.19# nmol/g/protein; *p<0.05 vs. WT-non; #p<0.05 vs. KO-non; n=4-6; 
Figure 4.4A)  
Isocitrate levels  
Isocitrate levels were significantly lower in KO hearts under non-ischemic conditions 
compared to WT hearts. Global ischemia led to a significant decrease in isocitrate levels in WT 
Figure 4.3. Glycogen and Lactate levels. Glycogen levels were measured in WT and KO hearts 
20 minutes post-ischemia using Nuclear Magnetic Resonance (NMR) spectroscopy, while 
lactate levels were measured in those hearts 20 minutes post-ischemia using IC-MS. *p<0.05 vs. 
WT-non; 
#
p<0.05 vs. KO-non; n=3-7. (+n) represents the number of 
13
C carbons incorporated 
into that metabolite.   
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hearts compared to their non-ischemic counterpart. Isocitrate levels remained unchanged in KO 
hearts compared to their non-ischemic counterpart with no significant difference between the two 
genotypes post-ischemia (WT-non, 147.89±51.30 nmol/g/protein; WT-isch, 5.48±2.70* 
nmol/g/protein; KO-non, 23.43±18.72* nmol/g/protein; KO-isch, 19.89±12.93 nmol/g/protein; 
*p<0.05 vs. WT-non; n=4-6; Figure 4.4B).  
α-ketoglutarate levels 
α-ketoglutarate levels were significantly higher in KO hearts under non-ischemic 
conditions compared to WT hearts. Global ischemia decreased α-ketoglutarate levels in both 
groups with no significant difference between the two genotypes post-ischemia (WT-non, 
1.20±0.27 nmol/g/protein; WT-isch, 0.23±0.11* nmol/g/protein; KO-non, 6.56±1.06* 
nmol/g/protein; KO-isch, 0.15±0.06# nmol/g/protein; *p<0.05 vs. WT-non; #p<0.05 vs. KO-non; 
n=3-7; Figure 4.4C).   
Succinate levels  
Succinate levels were significantly higher in KO hearts under non-ischemic conditions 
compared to WT hearts. Global ischemia increased succinate levels significantly in WT hearts, 
not in KO hearts (WT-non, 7.82±1.83 nmol/g/protein; WT-isch, 331.31±59.67* nmol/g/protein; 
KO-non, 37.94±4.84* nmol/g/protein; KO-isch, 86.71±34.26$ nmol/g/protein; *p<0.05 vs. WT-
non; $p<0.05 vs. WT-isch; n=3; Figure 4.4D).   
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Fumarate levels 
Fumarate levels were significantly higher in KO hearts under non-ischemic conditions 
compared to WT hearts. Global ischemia increased fumarate levels in both genotypes with no 
difference between the two groups (WT-non, 49.81±13.77 nmol/g/protein; WT-isch, 
204.89±53.14* nmol/g/protein; KO-non, 99.06±14.45* nmol/g/protein; KO-isch, 260.17±26.55# 
nmol/g/protein; *p<0.05 vs. WT-non; #p<0.05 vs. KO-non; n=4-6; Figure 4.4E).   
Malate levels  
Malate levels were not different between the two genotypes under non-ischemic 
conditions. Malate levels remained unchanged between the two groups post-ischemia when 
compared to their respective non-ischemic group. However, malate levels were significantly 
higher post-ischemia in KO hearts compared to WT hearts (WT-non, 110.99±34.93 
nmol/g/protein; WT-isch, 96.39±13.59 nmol/g/protein; KO-non, 206.01±102.89 nmol/g/protein; 
KO-isch, 221.62±36.31$ nmol/g/protein; $p<0.05 vs. WT-isch; n=5-7; Figure 4.4F). 
89 
 
 
 
Aspartate and Glutamate levels  
Aspartate and glutamate levels remained unchanged among the four groups (data not 
shown).  
ATP levels 
ATP levels were significantly higher in WT hearts under non-ischemic conditions 
compared to KO hearts. Global ischemia significantly decreased ATP levels in WT hearts 
Figure 4.4. TCA cycle metabolites. Levels of TCA cycle metabolites were measured in WT and 
KO hearts 20 minutes post-ischemia using IC-MS. A: Citrate. B: Isocitrate. C: α-ketoglutarate. 
D: Succinate. E: Fumarate. F: Malate. *p<0.05 vs. WT-non; 
#
p<0.05 vs. KO-non; 
$
p<0.05 vs. 
WT-isch; n=3-7. All (+n) metabolite data was pooled to yield total TCA cycle metabolite levels.          
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compared to their non-ischemic counterpart. ATP levels remained unchanged in KO hearts post 
ischemia (WT-non, 838.50±401.60 nmol/g/protein; WT-isch, 43.46±34.21* nmol/g/protein; KO-
non, 8.07±5.79* nmol/g/protein; WT-isch, 1.07±0.58 nmol/g/protein; *p<0.05 vs. WT-non; n=3-
7; Figure 4.5).  
 
AMPK activation and Glut4 expression 
Phosphorylation (activation) of AMPK was significantly higher in KO hearts under non-
ischemic conditions compared to WT hearts. Global ischemia decreased activation of AMPK in 
both groups. However, phosphorylation of AMPK remained significantly higher in KO hearts 
compared to WT hearts post-ischemia (*p<0.05 vs. WT-non; #p<0.05 vs. KO-non; $p<0.05 vs. 
WT-isch; n=4-5; Figure 4.6A).  
Figure 4.5. ATP levels. ATP levels were measured in WT and KO hearts 20 minutes post-
ischemia using IC-MS. *p<0.05 vs. WT-non; n=3-7.  
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Glut4 protein levels were not different between the two genotypes under non-ischemic 
conditions. Global ischemia significantly decreased Glut4 levels in KO group, not in WT 
(#p<0.05 vs. KO-non; $p<0.05 vs. WT-isch; n=4-5; Figure 4.6B).  
 
 
 
Akt and GSK-3β activation 
Phosphorylation (activation) of Akt was significantly higher in WT hearts under non-
ischemic conditions compared to WT hearts. Global ischemia significantly decreased Akt 
phosphorylation in both groups when compared to their respective non-ischemic group. There 
was no statistical difference in Akt phosphorylation between the two genotypes post-ischemia 
(*p<0.05 vs. WT-non; #p<0.05 vs. KO-non; n=5; Figure 4.7A).  
Phosphorylation at Ser-9 inactivates GSK-3β (14). Phosphorylation of GSK-3β was 
significantly lower in KO hearts under non-ischemic conditions compared to the WT hearts. 
Figure 4.6. AMPK activation and Glut4 expression. Heart lysates, prepared from WT and KO 
hearts, were analyzed by Western blot using anti-p-AMPK (A) and Glut4 (B) antibodies. Top: 
western blots exhibiting immunostaining for p-AMPK, Glut4, and GAPDH. Bottom: 
quantitative analyses of p-AMPK normalized to AMPK and Glut4 normalized to GAPDH 
(*p<0.05 vs. WT-non; 
#
p<0.05 vs. KO-non; 
$
p<0.05 vs. WT-isch; n=4-5).  
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Global ischemia decreased GSK-3β phosphorylation on both groups when compared to their 
respective non-ischemic group. There was no statistical difference in GSK-3β phosphorylation 
between the two genotypes post-ischemia (*p<0.05 vs. WT-non; #p<0.05 vs. KO-non; n=5; 
Figure 4.7B). 
 
 
 
Discussion 
A major finding of this study is that the lack of ATM accelerates glycolysis and 
gluconeogenesis and augments TCA cycle metabolism in the heart under non-ischemic 
conditions. Global ischemia augmented the gluconeogenic pathway in WT hearts, while it 
augmented the glycolytic pathway during ATM deficiency which associated with changes in 
TCA cycle metabolites. ATP levels were significantly lower in ATM deficient hearts. Global 
Figure 4.7. Akt and GSK-3β activation. Heart lysates, prepared from WT and KO hearts, 
were analyzed by Western blot using anti-p-Akt (A) and anti-p-GSK-3β (B) antibodies. 
Top: western blots exhibiting immunostaining for p-Akt, p-GSK-3β, and GAPDH. 
Bottom: quantitative analyses of p-Akt and p-GSK-3β normalized to Akt and GSK-3β 
(*p<0.05 vs. WT-non; 
#
p<0.05 vs. KO-non; n=5). 
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ischemia decreased ATP levels in both genotypes. These metabolic changes associated with 
alterations in the activity of AMPK, Akt, and GSK-3β as well as protein levels of Glut4.   
AT patients, patients with mutations in ATM gene, are predisposed to breast and 
pancreatic cancer and ischemic heart disease. These patients also show enhanced susceptibility to 
diabetes and impaired glucose metabolism (7, 33). In fact, AT patients exhibit lower metabolism 
in cerebellar hemisphere, anterior vermis and fusiform, while exhibiting higher metabolism in 
globus pallidus (34). This decreased metabolism in globus pallidus  correlated negatively with 
motor performance (34). Previously, our lab provided evidence that lack of ATM induces 
structural and functional changes in the heart with enhanced cardiac fibrosis and hypertrophy 
(18). Here we observed that lack of ATM results in enhanced glycolysis and gluconeogenesis at 
under non-ischemic conditions as evidenced by an increase in glycolytic metabolites such as 
G1P (+6), G6P (+6), F6P (+6), PEP (+3), and pyruvate (+3), and gluconeogenic metabolites such 
as G1P (+3) and F6P (+3) when compared to WT hearts. Additionally, ATP levels were lower in 
ATM null hearts under non-ischemia. This is consistent with the observations of Zakikhani et al. 
where glucose uptake and glycolysis were higher, while ATP levels were lower in MCF-7 and 
HepG2 cells treated with an ATM inhibitor KU-55933 (40). It was interesting to note that lack of 
ATM had no effect on glycogen and lactate levels under non-ischemic conditions. The enhanced 
glycolysis in ATM null hearts suggests metabolic stress. It is possible that glycolysis is enhanced 
in KO hearts as an attempt to replenish ATP levels and maintain somewhat proper functioning of 
the heart. However, these efforts may be restrained by enhanced gluconeogenesis, another mode 
by which homeostasis could be restored. It is also possible that glycogen levels remained 
unchanged under non-ischemic conditions in KO hearts due to rapid cycling of both glycolytic 
and gluconeogenic pathways. 
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The metabolic demand of the heart per gram is the highest in the body (37). Adequate 
amount of ATP must be generated to support the contractile activity of the heart and to support 
viability (37). About 4% of ATP in the heart is derived from glycolysis, while >95% of ATP is 
derived from oxidative phosphorylation at the electron transport chain in mitochondria (37). 
Cardiac ischemia associates with dramatic changes in metabolism. Due to depletion of O2, 
mitochondrial oxidative phosphorylation decreases, while glycolysis accelerates (27). Since 
mitochondria are unable to oxidize pyruvate, pyruvate is converted into lactate (27). As 
expected, global ischemia decreased ATP levels and glycogen levels in WT hearts. Global 
ischemia also associated with increased levels of gluconeogenic metabolites, such as G1P (+3), 
G6P (+3), and F6P (+3). The levels of glycolytic metabolites, PEP (+3) and pyruvate (+3), were 
significantly lower in ischemic WT hearts. Levels of lactate tended to be higher with ischemia, 
although the data remained insignificant. These data point towards the augmentation of the 
gluconeogenic pathway in WT hearts post-ischemia. Furthermore, the decrease in glycogen 
levels post-ischemia is indicative of glycogen breakdown. Glycogen is a critical energy 
repository in the heart and can quickly be mobilized if needed (35). During energy deficiency, 
glycogen breakdown is enhanced to accommodate the rapid changes in cardiac demand (35). In 
rat kidney, 30 minutes of ischemia led to enhanced gluconeogenesis (23). Gluconeogenesis is 
suggested to be correlated with glycogen metabolism in rabbit hearts during ischemia and 
reperfusion as ischemia (5 minutes) decreased glycogen levels and increased the expression of 
phosphoenolpyruvate carboxykinase, an important enzyme involved in the regulation of 
gluconeogenesis (1). Given that there is no significant change in lactate levels, and the levels of 
glycolytic metabolites PEP (+3) and pyruvate (+3) are lower in WT hearts post-ischemia, it is 
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possible that PEP (+3) and pyruvate (+3) contribute to the gluconeogenic pathway. It is also 
possible that glycogen is mobilized in WT hearts post-ischemia for gluconeogenesis.  
In contrast to WT hearts, ATP levels were lower in KO hearts and remained unchanged 
post-ischemia. Interestingly, non-ischemic levels of glycolytic metabolites - G1P (+6), G6P (+6), 
F6P (+6), PEP (+3), and pyruvate (+3) were significantly greater in KO hearts vs WT hearts. 
Global ischemia decreased the levels of these metabolites with no difference between the two 
genotypes. Two gluconeogenic metabolites GIP (+3) and F6P (+3) were also greater in non-
ischemic KO hearts and global ischemia had no effect on gluconeogenic metabolites. Like WT 
hearts, global ischemia decreased glycogen levels with no change in lactate levels. It appears that 
global ischemia augments the glycolytic pathway in KO hearts. The decrease in glycogen stores 
coupled with the decrease in glycolysis may indicate a preference for glycogen metabolism as 
opposed to metabolizing exogenous glucose in KO hearts post-ischemia.  
Additionally, global ischemia decreased levels of citrate, isocitrate, and α-ketoglutarate, 
while increasing levels of succinate and fumarate. Since the TCA cycle is oxygen-dependent, the 
levels of TCA cycle metabolites citrate, isocitrate, and α-ketoglutarate are expected to be lower 
in WT hearts post-ischemia. Unexpectedly, ischemia elevated levels of succinate and fumarate in 
WT hearts. Succinate is suggested to play a critical role in the heart’s response to ischemia-
reperfusion injury, and is considered as a universal signature of ischemia (5, 30) as its 
accumulation has been seen during hypoxia in isolated adult rat heart cells (21) and in isolated 
mouse hearts (2). The sources of increased succinate can include the conversion of aspartate and 
glutamate to succinate (2) or reduction of malate to succinate via the reverse reaction of 
succinate dehydrogenase during ischemia (2, 30). Of note, accumulation of fumarate is suggested 
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to play a cardioprotective role (2). Therefore, it is possible that enhanced production of succinate 
and fumarate from amino acid metabolism may be an attempt to generate energy through 
intermediary metabolism, while playing a protective role to reverse/negate the negative 
consequences of cardiac ischemia.     
KO mice also exhibited altered TCA cycle metabolism under non-ischemic conditions. 
Isocitrate levels were lower, while α-ketoglutarate, succinate, and fumarate levels were higher in 
KO hearts. The decrease in isocitrate levels could be due to the usage of pyruvate to fuel 
glycolytic and gluconeogenic cycling as opposed to being utilized to drive the TCA cycle. The 
increase in the levels of α-ketoglutarate, succinate, and fumarate may in part be attributable to 
anaplerosis of the TCA cycle. Amino acids play a critical role in cardiac metabolism, as they are 
regarded as cardioprotective substrates and produce low levels of acidic by-products (12). 
Glutamate, a key amino acid in cellular metabolism, can easily be converted to α-ketoglutarate in 
times of stress (12). Aspartate has the ability to remove excess TCA cycle intermediates 
downstream from the conversion to succinate (12). Here, glutamate and aspartate levels were not 
significantly different between the two non-ischemic groups. It is possible that substrates other 
than glutamate and aspartate may contribute to α-ketoglutarate formation in KO hearts. Global 
ischemia decreased citrate and α-ketoglutarate levels in both genotypes, however, fumarate 
levels were increased in KO hearts, indicating that the TCA cycle may be defective or down-
regulated in KO hearts during global ischemia. Fumarate levels may be higher due to its potential 
cardio-protective effect. Despite the robust changes seen in KO hearts under non-ischemic 
conditions when compared to WT hearts, global ischemia had no effect on the glycolytic and 
gluconeogenic pathways in KO hearts. It appears that KO hearts are metabolically stressed 
without the superimposed insult.  
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AMPK is a key component of many metabolic pathways in the heart, as it serves to 
maintain cellular homeostasis (20, 26, 28, 39). AMPK is activated in response to an increase in 
the AMP:ATP ratio and metabolic stresses like ischemia and oxidative stress (20, 26, 28, 39). In 
fact, AMPK is a key regulator of glucose metabolism as its activation triggers catabolic 
pathways like glycolysis to produce ATP (20, 26, 28, 39), while turning off anabolic pathways 
that utilize ATP such as gluconeogenesis (26, 39). In order to increase glucose uptake, AMPK 
increases GLUT1 expression and GLUT4 translocation to the plasma membrane (20, 28, 32, 35). 
However, GLUT1 is the predominant glucose transporter in the fetal heart, while GLUT4 is the 
predominant form in the adult heart (10, 11). In fact, after birth GLUT4 replaces GLUT1 
yielding a 20-fold decrease in GLUT1 and a 4-fold increase in GLUT4 mRNA and protein (10). 
While GLUT1 is important for basal glucose uptake in the fetal heart, GLUT4 mediates glucose 
uptake in the adult heart and is correlated with sustained cardiac function (10, 11). Here we 
observed that AMPK activity is higher in KO non-ischemic hearts. Global ischemia decreased 
AMPK activity in both genotypes. On the other hand, GLUT4 expression was not different 
between the two non-ischemic groups. Global ischemia decreased GLUT4 expression in KO 
group, not in WT group. The observation of higher AMPK activity in non-ischemic KO hearts is 
consistent with the observations Zakikhani et al. where AMPK phosphorylation was increased in 
MCF-7, HeLa, and HepG2 cells treated with the ATM inhibitor KU-55933 (40). This increased 
AMPK activation may be a response to low ATP levels in KO hearts under non-ischemic 
conditions. Although GLUT4 protein levels were not significantly different between WT and KO 
groups under non-ischemic conditions, high AMPK activation may explain the accelerated 
glycolysis. On the other hand, decreased AMPK activation in WT hearts post-ischemia may 
explain the increase in gluconeogenic metabolites to maintain homeostasis in the face of 
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ischemic stress, while AMPK activation in KO hearts post-ischemia may be correlated with low 
GLUT4 protein levels and glycolysis.  
Akt signaling plays a key role in cell survival and glucose metabolism (4, 6, 36). In 
cancer cells, Akt signaling associates with an increase in glucose metabolism (6). Akt promotes 
glucose uptake by increasing GLUT1 expression on the cell surface and promoting the 
translocation of GLUT4 to the plasma membrane (4, 36). Akt also affects glucose metabolism by 
phosphorylating or inactivating GSK-3β, which in turn stimulates glycogen synthesis (25, 29). 
Ischemia increases GSK-3β transcription in rabbit hearts, followed by a decrease in glycogen 
content, suggesting that glycogen consumption during ischemia is regulated by GSK-3β (15). In 
the present study, non-ischemic KO hearts exhibited decreased Akt activation and increased 
GSK-3β activation versus the WT non-ischemic hearts. Previously, our lab reported no 
significant change in phosphorylation of Akt and GSK-3β between WT-sham and KO-sham 
groups (18). It should be noted that hearts in the present study were subjected to a 30 minute 
perfusion with KH buffer post-excision prior to the preparation of heart lysates. Furthermore, the 
previous study used LV lysates for western blot analyses (18), while the current study used 
whole heart lysates. Interestingly, glycogen levels were comparable between the two genotype, 
supporting the possibility of rapid cycling of both glycolytic and gluconeogenic pathways in KO 
hearts. Global ischemia enhanced GSK-3β activity, while decreasing Akt activity and glycogen 
levels. These data suggest that glycogen consumption is regulated by Akt/GSK-3β pathway in 
both genotypes post-ischemia. In the KO hearts, however, Akt activity may also be involved in 
Glut4 expression as Glut4 protein levels were lower in KO hearts post-ischemia as well.  
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In summary, we provide evidence that the lack of ATM accelerates glycolysis and 
gluconeogenesis in the heart during non-ischemic conditions to augment TCA cycle metabolism. 
Global ischemia augments the gluconeogenic pathway in WT hearts, while it augments the 
glycolytic pathway during ATM deficiency which associates with changes in TCA cycle 
metabolites. Additionally, global ischemia had no effect on glycolytic or gluconeogenic 
pathways in KO hearts, suggesting the possibility that the KO hearts are already metabolically 
stressed under non-ischemic conditions. The aforementioned metabolic changes associated with 
changes in the activity of signaling kinases such as Akt, GSK-3β, and AMPK, and Glut4 protein 
levels. Together, these data support the finding that ATM affects cardiac metabolites with and 
without ischemia. However, it should be emphasized that our data on ATM deficiency and 
metabolic changes are obtained 20 minutes post-global ischemia. A thorough time course 
analysis of various metabolites and signaling molecules involved metabolism may provide 
further insights into the mechanism by which ATM affects cardiac energetics.  
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CHAPTER 5 
CONCLUSION 
Mutations in ATM gene cause a multisystemic disease known as Ataxia telangiectasia 
(AT) (Lavin et al. 1995; Su and Swift 2000). AT patients are susceptible to ischemic heart 
disease  and metabolic disorders (Lavin et al. 1995; Su and Swift 2000). Using ATM deficient 
mice, this study investigated the role of ATM in cardiac autophagy and glucose metabolism 
under ischemic conditions. A major finding of this study is that ATM deficiency results in 
autophagic impairment in the heart 4 hours during MI and 4 hours post- inhibition in cardiac 
fibroblasts, while it augments autophagic response in the infarct region of the heart 28 days post-
MI and 24 hours post-inhibition in cardiac fibroblasts. Early during MI (4 hours after its onset), 
ATM deficiency resulted in autophagic impairment in all phases (autophagy induction, 
autophagosome formation, and autophagolysosome degradation) and in cardiac fibroblasts via 
the activation of GSK-3β and mTOR, and inactivation of Akt and AMPK. Late during MI (28 
days post-MI), ATM deficiency augmented autophagy only in the infarcted region of the heart, 
which associated with the activation of Erk1/2, Akt and mTOR. Additionally, ATM affected 
glucose metabolism with and without ischemia. The lack of ATM accelerated glycolysis and 
gluconeogenesis, and augmented TCA cycle metabolism under non-ischemic conditions. Global 
ischemia augmented the glycolytic, not the gluconeogenic, pathway during ATM deficiency. 
Such metabolic changes associated with alterations in the activity of AMPK, Akt, and GSK-3β 
as well as protein levels of Glut4. Overall, the data presented here implicates ATM as a key 
player in autophagic changes in the heart in response to MI as well as in glucose metabolism 
under non-ischemic and ischemic conditions.  
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ATM and Cardiac Autophagy 
Early during MI (4 hours after its onset), ATM deficiency impaired autophagy in the 
heart at all three stages (autophagy induction, autophagosome formation, and 
autophagolysosome degradation) and in cardiac fibroblasts treated with the ATM inhibitor KU-
55933 for 4 hours. Such autophagic changes in the heart and in cardiac fibroblasts associated 
with the activation of GSK-3β and mTOR, and inactivation of Akt and AMPK. Although 
typically associated with apoptotic signaling (Endo et al. 2006), Akt/ GSK-3β signaling has also 
been implicated in autophagy regulation. Akt activation (phosphorylation) and GSK-3β 
inactivation (phosphorylation) induces autophagy following middle cerebral artery occlusion that 
ultimately results in neuroprotection in the transient cerebral ischemic rat model (Qi et al. 2012). 
Furthermore, the GSK-3β inhibitor CHIR99021 induced an autophagic response in human 
pancreatic cancer cells (Marchand et al. 2015). Additionally, GSK-3β activity has been linked to 
AMPK activity, the energy sensor in cells that functions to maintain homeostasis by responding 
to ATP depletion. Suppression of GSK3β using CHIR99021 in human aortic endothelial cells 
resulted in increased basal autophagy and AMPK activity (Weikel et al. 2016). It is well-known 
that AMPK activation activates autophagy and can do so via inactivating the master regulator of 
autophagy, mTOR (Chang Hwa Jung, Seung-Hyun Ro, Jing Cao, Neil Michael Otto 2010; Kim 
et al. 2011; Kim and L. 2015). Thus, it is possible that inactivation of Akt leads to the activation 
of in GSK-3β phosphorylation, thus activating GSK-3β. Increased GSK-3β activity may result in 
a decline in AMPK phosphorylation and activation. This decline in AMPK activation may result 
in mTOR activation that ultimately inhibits autophagic response. Interestingly, ATM deficiency 
resulted in enhanced autophagic response under basal conditions. However, such autophagic 
changes did not associate with alterations in Akt, GSK-3β, or AMPK activity. However, mTOR 
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phosphorylation was lower in ATM deficient hearts, indicating that enhanced autophagic 
response in ATM deficient hearts under basal conditions may be mTOR dependent. Together, 
these data suggest that ATM deficiency serves a pro-autophagic role under basal conditions that 
changes upon the onset of MI, and that the signaling molecules involved in ATM-mediated 
autophagic response are different under basal conditions and early during MI. 
ATM deficiency also augmented autophagy the infarct region of the heart 28 days post-
MI as well as in cardiac fibroblasts treated with ATM inhibitor KU-55933 for 24 hours. 
Augmented autophagy in the infarct region of the hearts associated with enhanced Akt, Erk1/2, 
and mTOR activation. Activation of Akt and Erk1/2 is shown to positively regulate autophagy 
(Suffixidharan et al. 2011), while activation of mTOR is known to negatively regulate autophagy 
(Chang Hwa Jung, Seung-Hyun Ro, Jing Cao, Neil Michael Otto 2010). Thus, it is possible that 
the autophagic changes in ATM deficient hearts post-MI involves both Akt and Erk1/2 signaling 
that is independent of mTOR activation. Furthermore, we previously found that activation of 
GSK-3β was lower in the infarct region of ATM deficient hearts compared to their WT 
counterparts (Daniel et al. 2016). Of interest is to note that the decrease in GSK-3β activity 
associated with a decrease in apoptosis in the infarct region of the heart (Daniel et al. 2016). As 
GSK-3β is a downstream target of Akt (Fang et al. 2000), it is possible that activated Akt 
phosphorylated and inhibited (phosphorylated) GSK-3β. Such inhibition of GSK-3β, a pro-
apoptotic kinase (Daniel et al. 2016), could have resulted in the decrease in apoptosis and 
changes in autophagy.  
While autophagy is typically enhanced following MI, there have been contrasting reports 
of autophagic activity in the non-infarct region of the heart following MI. For instance, Chi et al. 
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showed that LC3 protein expression revealed that LC3 protein levels were significantly lower in 
the remote non-infarcted region of the rabbit hearts 1, 4 and 8 weeks after MI compared with 
sham animals (Chi et al. 2018). Furthermore, Beclin1 and Atg5 protein expression was 
significantly lower in the remote non-infarcted region 4 weeks post-MI compared with sham 
animals (Chi et al. 2018). Although statistically insignificant, p62 protein levels tended to 
increase 4 weeks post-MI compared with sham animals (Chi et al. 2018). On the other hand, it 
has also been shown that autophagic activity is augmented in the non-infarcted remote area and 
border area post-MI, and the autophagic activity progressively increases in the remote area up to 
3 weeks post-MI (Kanamori, Takemura, Goto, Maruyama, Tsujimoto, et al. 2011; Kanamori et 
al. 2013). In the current study, we observed increased LC3-II protein levels and decreased p62 
protein levels in WT non-infarct LV 28 days post-MI, suggesting autophagic alterations. 
Interestingly, ATM deficiency did not affect autophagic response in the non-infarct LV region 28 
days post-MI. Thus, it is presently unclear why autophagic activity was unchanged in the non-
infarct region of the heart 28 days post-MI in response to ATM deficiency and such a 
phenomenon warrant future investigations.  
Collectively, these results indicate that ATM deficiency serves to enhance autophagy 
under basal conditions while also augmenting autophagic activity in the infarct region during a 
chromic model of MI (28 days post-MI) and 24 hours post ATM inhibition in cardiac fibroblasts. 
However, during the early stages of MI (4 hours during MI) and 4 hours following ATM 
inhibition in cardiac fibroblasts, ATM deficiency impairs autophagic response. While autophagic 
enhancement during ATM deficiency is mTOR dependent under basal conditions, its 
augmentation is mTOR independent in the infarct region 28 days post-MI. Furthermore, 
autophagic response during ATM deficiency in the heart and in cardiac fibroblasts does not seem 
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to involve other signaling molecules (Akt, GSK-3β, Erk1/2, AMPK) until the onset of MI. Four 
hours after the onset of MI, autophagic impairment is driven by inactivation of Akt and AMPK, 
and activation of GSK-3β and m-TOR. On the contrary, autophagic changes in the infarct region 
28 days post-MI associates with activation of Akt, Erk1/2, and mTOR and inactivation of GSK-
3β. These results suggest that the role of ATM in autophagic response changes over the time 
course of MI (ATM deficiency has different effects in autophagy 4 hours into MI as opposed to 
28 days post-MI), and the mechanisms by which these changes occur with time are also 
different. Thus, future investigations involving intermediate time points between 4 hours and 28 
days post-MI should be conducted to understand the full scope of molecular changes involved in 
autophagic flux during ATM deficiency post-MI. Also, the utilization of autophagy inhibitors 
and activators in future studies may help elucidate the mechanisms by which ATM deficiency 
alters autophagy post-MI.       
ATM and Cardiac Glucose Metabolism 
Another interesting major finding of this investigation is that the lack of ATM accelerates 
glycolysis and gluconeogenesis, and augments TCA cycle metabolism under non-ischemic 
conditions. Additionally, ATP levels were lower in ATM null hearts under non-ischemia, while 
glycogen levels were comparable between WT and KO hearts. The enhanced glycolysis in ATM 
null hearts suggest metabolic stress. It is possible that glycolysis is enhanced in KO hearts as an 
attempt to replenish ATP levels and proper functioning of the heart. However, these efforts may 
somewhat be restrained by enhanced gluconeogenesis, another mode by which homeostasis 
could be restored (Aguiar et al. 2017). It is also possible that glycogen levels remained 
unchanged under non-ischemic conditions in KO hearts due to rapid cycling of both glycolytic 
109 
 
and gluconeogenic pathways. Furthermore, 20 minute global ischemia down-regulated the 
glycolytic pathway, not the gluconeogenic pathway, during ATM deficiency. Glycogen stores 
were also significantly reduced in ATM null hearts post-ischemia. Glycogen is a critical energy 
repository in the heart and can quickly be mobilized if needed (Wang et al. 2014). During energy 
deficiency, glycogen breakdown is enhanced to accommodate the rapid changes in cardiac 
demand (Wang et al. 2014). When coupled with decreased glycolysis, a decrease in glycogen 
levels indicate a preference for glycogen metabolism as opposed to metabolizing exogenous 
glucose in KO hearts post-ischemia.   
AMPK is a key regulator of glucose metabolism as its activation triggers glycolysis to 
produce ATP (Long and Zierath 2006; Heidrich et al. 2010; Wu and Wei 2012). To increase 
glucose uptake, AMPK increases GLUT1 expression and GLUT4 translocation to the plasma 
membrane (Heidrich et al. 2010). Like AMPK, Akt promotes glucose uptake by increasing 
GLUT1 expression on the plasma membrane and promoting the translocation of GLUT4 to the 
plasma membrane (Chaanine and Hajjar 2011; Ward and Thompson 2012). Akt also 
phosphorylates or inactivates GSK-3β, which in turn stimulates glycogen synthesis (Oreña et al. 
2000; Lee and Kim 2007). Here, activation of AMPK was higher in ATM null hearts under non-
ischemic conditions, suggesting its involvement in the accelerated glycolysis in response to low 
ATP levels. However, global ischemia decreased AMPK activation in ATM null hearts, a 
phenomenon that may explain low GLUT4 protein expression and glycolysis in these hearts. 
Global ischemia enhanced GSK-3β activity, while decreasing Akt activity in KO hearts. These 
data suggest that glycogen consumption is regulated by Akt/GSK-3β pathway in KO hearts post-
ischemia, and that Akt activity may also be involved in Glut4 expression as Glut4 expression 
was lower in those hearts post-ischemia as well.  
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ATM null hearts exhibited altered TCA cycle metabolism under non-ischemic conditions. 
Isocitrate levels were lower, while α-ketoglutarate, succinate, and fumarate levels were higher in 
null hearts. The decrease in isocitrate levels could be due to the usage of pyruvate to fuel 
glycolytic and gluconeogenic cycling as opposed to being utilized to drive the TCA cycle. 
Succinate plays a critical role in the heart’s response to ischemia-reperfusion injury and is 
considered a universal signature of ischemia (Chouchani et al. 2014; Pell et al. 2016). 
Accumulation of fumarate is suggested to play a cardioprotective role (Ashrafian et al. 2012). 
The increase in the levels of α-ketoglutarate, succinate, and fumarate may in part be attributable 
to the contribution of amino acid metabolism. Global ischemia decreased citrate and α-
ketoglutarate levels in null hearts, however, fumarate levels were increased, indicating that the 
TCA cycle may be defective or down-regulated in the absence of ATM during global ischemia. 
Fumarate levels are higher due to its potential cardio-protective effect. 
Altogether, these results indicate that the lack of ATM results in accelerated 
gluconeogenesis and glycolysis under non-ischemic conditions and that global ischemia down-
regulates glycolysis in ATM null hearts. Such changes were also accompanied by alterations in 
TCA cycle metabolism that may serve as cardio-protective. Overall changes in glucose 
metabolism in ATM null hearts were driven by alterations in the activity of AMPK, Akt, and 
GSK-3β as well as protein levels of Glut4. Although these findings are novel and hold the 
potential to shed light on the role of ATM in glucose metabolism, a thorough time course 
analysis of various metabolites and signaling molecules involved metabolism is needed to 
provide further insights into the mechanism by which ATM affects cardiac energetics.  
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